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As more patients with cystic fibrosis (CF) are living into adulthood, patients may need to 
disclose their CF status to others, such as in romantic or professional settings. Patients who 
choose not to disclose their CF status may be limited in their closeness with others, which may 
negatively affect their psychological functioning and health-related quality of life. Few studies, 
however, have examined disclosure in CF, and currently no validated measures of CF disclosure 
 
 
 
 
exist. The purpose of this study was to explore CF disclosure in adults and validate a new 
assessment of CF disclosure, the Cystic Fibrosis Disclosure Scale (CFDS). 
Results were consistent with prior research in disclosure in CF, with participants 
disclosing most often to close others and less often at school or in the workplace. Disclosure to 
close and casual friends was consistently associated with better psychosocial functioning. Factor 
analyses determined the CFDS was valid and that all questions should be retained. The Count 
Group subscale emerged as the “best” subscale grouping and coding method. This study 
contributed to the literature by serving as the first validation study of a questionnaire of 
disclosure in CF. Additionally, as disclosure in CF is a new emerging area, this study added 
information to the sparse literature on this issue. The CFDS as it exists now gathers important 
research and clinical information from adults with CF, and should be examined further with a 
larger sample size and more descriptive information. 
 
 
 
 
1 
Scoring and Validation of the Cystic Fibrosis Disclosure Questionnaire 
Cystic fibrosis (CF) is an inherited disorder which causes many health complications, 
primarily poor respiratory functioning and malabsorption of nutrients (Cystic Fibrosis 
Foundation [CFF], 2013). Approximately 30,000 Americans currently have CF, and 1,000 new 
cases are diagnosed each year (CFF, 2013). Although CF can occur in all ethnicities, it is most 
commonly found in Caucasians of Northern European descent (Centers for Disease Control and 
Prevention [CDC], 2007). Chronic health problems, inherent in CF, can be exacerbated into 
acute crises; in the early stages of CF research and treatment, children with CF typically died 
before reaching adolescence. The average life expectancy for individuals with CF has increased 
to 37 years (CDC, 2007). 
CF is a complex chronic illness to manage. Successful management of CF requires an 
intensive regimen to help lungs and digestive systems work properly. Most research in CF has 
focused on issues in childhood and adolescence (Ball et al., 2013; Thompson, Gustafson, 
Hamlett, & Spock, 1992; Tluczek et al., 2013), the transition of care into adult services 
(Kreindler & Miller, 2013; Okumura et al., 2014), patient-provider communication (Blackwell, 
Marciel, & Quittner, 2013), and treatment adherence (Flores, Teixeira, Rovedder, Ziegler, & 
Dalcin, 2013; Glauser et al., 2012). As the number of adults with CF grows, the transition to 
adulthood requires disclosure of CF status in multiple areas (e.g., romantic, family, professional). 
Few studies, however, have examined disclosure in CF. Disclosure is defined as “the act of 
making something known” (Merriam Webster, 2014). In the context of CF, disclosure refers to 
telling someone, implicitly or explicitly, about one’s diagnosis. Disclosure may be viewed as a 
spectrum, from not disclosing anything about CF to being fully open about CF and performing 
CF treatments in front of other people. The proposed study validated a new assessment of CF 
disclosure, the Cystic Fibrosis Disclosure Scale (CFDS). Currently, no validated measures of 
CF disclosure exist. 
 
 
2 
Disclosure 
Illness disclosure is a relatively new area in CF, and in chronic illness in general. The 
literature to date on disclosure in CF has been largely qualitative, although there has been 
quantitative research conducted in other health areas (e.g., HIV; Joachim & Acorn, 2000). A 
review of existing theories of illness disclosure and factors associated with disease disclosure are 
discussed below. 
Theory. Goffman’s work on stigma and management of stigmatizing information in 
social settings is the foundation for many illness disclosure theories (1959; 1963). Bird and 
Voisin (2010) created a conceptual model of HIV disclosure that weighed perceived stigma, 
beliefs about disclosure risk and privacy, partner characteristics, and the sexual context when 
deciding whether or not to disclose HIV-status. The authors strongly weighted the impact of 
stigma on constructs in the model when designing the framework, believing that stigma drives 
the development of other variables. Bairan and colleagues developed another model for HIV-
status disclosure (2007). Their model has two categories of relationships: sexual and non-sexual. 
In the sexual relationship category, the decision to disclose is influenced by the intensity of the 
relationship (short-term casual sex partner vs. long-term committed relationship). In non-sexual 
relationships, the decision to disclose is similarly placed along a spectrum of intimacy (less 
likely to disclose to strangers, more likely to disclose to family members). Stigma is also 
considered in the decision to disclose, although it is not the central variable in this model.  
Chaudoir and Fisher (2010) developed a theory of disclosure entitled the Disclosure 
Processes Model (DPM). The DPM posits that the disclosure decision is a reinforcing loop that 
consists of antecedent goals, the disclosure event itself, mediating processes and outcomes, and a 
positive or negative feedback loop. Essentially, the experiences that people have with disclosing 
their illness status determines how likely they are to disclose again in the future. This model 
 
 
3 
could be applied to several chronic illnesses, including CF because it is based on general 
experience and human behavior. 
Finally, a study conducted by Admi interviewed CF patients about their experiences with 
disclosure (1995). Participants chose specific “telling strategies” when disclosing illness status 
according to the perceived ability of the audience to deal with the information and the situational 
context. Four strategies of managing disease-related information were identified: visibility (e.g., 
doing treatments in front of others), direct telling (e.g., oral or written disclosure of diagnosis and 
provision of information), silent telling (e.g., acting as though people know without ever having 
told them), and concealment (e.g., pretending CF symptoms are asthma symptoms). According 
to participants, disclosure increased as participants aged and gained more understanding of CF 
and its implications, as well as situational factors associated with disclosure. Based on this 
information, Admi concluded that disclosure is dictated by three factors: the audience, which 
“telling strategy” is employed, and the person with CF’s “stage of telling.” Models of Admi’s 
disclosure theory are depicted below in Figures 1 and 2. 
 Figure 1. Codes and clusters of managing CF information (Admi, 1995). 
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Factors associated with disclosure. As evidenced above by multiple theories of HIV 
disclosure, a major area of disclosure research has been in sexually transmitted infections (STI). 
Understandably, stigma plays a large role in the decision to disclose in this population, and 
higher perceived stigma is associated with lower levels of disclosure (Derlega, Winstead, 
Greene, Serovich, & Elwood, 2002; Derlega, Winstead, Gamble, Kelkar, & Khuanghlawn, 
2010). In a study of women with HPV, participants were most likely to disclose their diagnosis 
to sexual partners, female friends, and their mothers (Daley et al., 2010). These results were 
confirmed in a study of women with iatrogenically-acquired Hepatitis C (Dunne & Quayle, 
2002). 
The decision to disclose illness status has also been consistently linked to social support 
(Gignac & Cao, 2009; Merin & Pachankis, 2011). Disclosure has been positively linked with 
coping and physical health (Pennebaker, Kiecolt-Glaser, & Glaser, 1988), but social support has 
been found to mediate this association (Beals, Peplau, & Gable, 2009; Major et al., 1990). A 
study of adults with Rheumatoid Arthritis found that strong social networks resulted in better 
Figure 2. Theoretical framework of managing CF information (Admi, 1995). 
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emotional coping and physical health (Holtzman, Newth, & Delongis, 2004). Adolescents with 
sickle cell disorder reported being more likely to disclose than withhold their diagnosis due to 
safety reasons (e.g., if their teacher knows, they can take appropriate action if they are ill). 
Reasons against disclosing in this sample included appearing different, not wanting their disease 
to define them, and fear of discrimination (Dyson et al., 2010). 
Potential outcomes of disclosure seem to vary among studies. Barnack-Tavlaris and 
colleagues (2011) found that a high level of disclosure of genital herpes was associated with a 
lower quality of life in women. In a study of women with Hepatitis C (Hopwood, Nakamura, & 
Treloar, 2010), 52% of participants reported receiving poor reactions from people to whom they 
decided to disclose their diagnosis, and approximately 38% regretted telling someone about their 
diagnosis. Participants who reported more negative effects from Hepatitis C had disclosed more 
widely than those who did not report these effects. In sum, factors such as social support, type of 
relationship, level of education, and stigma seem to be associated with disclosure in multiple 
health conditions. 
Cystic Fibrosis 
In understanding the importance of disclosure, it is important to first understand the 
challenges that an adolescent or young adult with CF may encounter. CF symptoms will be 
reviewed first, followed by a summary of current CF treatments and CF adherence.  
Overview of CF symptoms. Symptoms of CF can vary widely in severity and 
occurrence, and affect almost every system in the human body. CF is a progressive illness with 
increasing periods of worsened health, frequent hospitalizations, and more visible treatments. 
Symptoms often mandate disclosure due to their far-reaching effects and visibility. The most 
severely impacted area is the respiratory system. Patients diagnosed with CF are born with 
normally functioning lungs; however, as time goes on, thick mucus develops, commonly 
resulting in recurrent bronchitis and infections (Bluebond-Langner, Lask, & Angst, 2001). 
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Severe complications include bronchiestasis, collapsed lung, and lung and right heart failure. 
Therapies attempt to control symptoms and delay disease progression as there is no cure for 
respiratory symptoms of CF. 
A second area impacted by CF is the pancreatic system. Eighty-five to ninety percent of 
those with CF display a failure to digest nutrients (Wilcken, Towns, & Mellis, 1983). Children 
and adults are usually thin and/or malnourished at time of diagnosis, and have greater energy 
requirements than those without CF (Vaisman, Pencharz, Corey, Canny, & Hahn, 1987). This 
combination of higher energy needs and inability to absorb nutrients blocks normal growth in 
children and adolescents with CF. Poor nutrition also negatively impacts lung function, 
exacerbating existing problems in that area. Beyond malabsorption of nutrients, 30% of patients 
with CF develop diabetes by age twenty-five due to pancreatic dysfunction (Lanng, 
Thorsteinsson, Erichsen, Nerup, & Koch, 1991). Classic diabetic complications, such as 
neuropathy and retinopathy, can occur in those with CF, adding an extra burden to patients 
(Sullivan & Denning, 1989). 
A third organ impacted by CF is the liver. Lesions on the liver develop due to cirrhosis 
and hypertension, although this does not happen to all patients. This can lead to hypersplenism, 
traumatic splenal rupture, or gastrointestinal bleeding (Psacharopoulos, Howard, Portmann, 
Mowat, & Williams, 1981).  
The final system significantly impacted by CF is the genital and reproductive system. 
Men and women with CF often experience delayed puberty and menarche, and women also 
commonly experience amenorrhea due to complications mentioned above (Stead et al., 1987b). 
Women also typically have reduced fertility and are urged to stabilize lung function before 
attempting pregnancy (Edenborough, Stableforth, Webb, Mackenzie, & Smith, 1995), while 98% 
of men with CF are infertile due to mucus clogging the vas deferens (Brugman & Taussig, 1984). 
Other health concerns can occur as a result of CF. These include, but are not limited to, 
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hemoptysis, clubbed fingers, small joint polyarthritis (Bluebond-Langner et al., 2001), 
osteopaenia (Haworth et al.,1999), and generalized vasculitis (Hodson, 1992). 
Overview of CF treatments. Because CF impacts so many organs, regimens are 
complex and typically have multiple goals. The most common aims of CF treatment are to 
prevent and control lung infections, loosen and remove mucus from the lungs, prevent and treat 
mucus in the intestines, and ensure adequate nutrition (Mayo Clinic, 2008). In addition to 
experiencing symptoms of CF that may necessitate disclosure, oftentimes aspects of the 
treatment regimen may also contribute to decisions around disclosure. As CF worsens, 
treatments become more visible (e.g., oxygen therapy). Components of the CF regimen are 
briefly outlined below. 
Respiratory therapies. No matter how severe the illness, chest physiotherapy (CPT) is 
always recommended (Bluebond-Langner et al., 2001). Multiple CPT methods exist, including 
active cycle of breathing (a three-part combination of relaxation, deep breathing, and huffing to 
expectorate mucus), postural drainage (positioning the body so the trachea is inclined downward 
and below the chest area, thereby draining the mucus), autogenic draining (taking deep breaths 
and exhaling in sighing patterns to loosen mucus in the lungs), positive expiratory pressure 
(PEP) mask (forces air into the lungs and moves phlegm from the airways), flutter valve (patients 
exhale through the device and rapid air pressure fluctuates in the airways, causing vibrations that 
loosen mucus), and thAIRapy (a vest that uses a compressor to inflate and deflate the vest 
rhythmically at timed intervals to oscillate the chest wall and thin the mucus; Bush, 2001). Most 
patients employ a primary CPT method, and a secondary technique used when away from home. 
The vest is the most common treatment and should be used for thirty minutes twice per day 
(more frequently when symptoms are worse). Bronchodilators are also prescribed in inhaled or 
nebulized forms to be used before CPT to dilate the lungs and help loosen mucus (Tiddens & 
Devadason, 2007). 
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The second component of the respiratory regimen is inhalation of an enzyme called 
dornase alfa (DNase). DNase renders the mucus less viscous when inhaled from a nebulizer, 
improving airway clearance when used in conjunction with CPT. Use of DNase is recommended 
for everyone diagnosed with CF age six or older (Mogayzel et al., 2013). 
Another part of the respiratory regimen is inhaled hypertonic saline. For CF patients age 
six and older, CF guidelines recommend the use of inhaled hypertonic saline twice daily to 
improve lung function and reduce exacerbations (Mogayzel et al., 2013). Hypertonic saline is 
delivered through an inhaled mist using a nebulizer. 
A final common component of respiratory therapy is antibiotics. Chronic antibiotic use is 
initiated when the CF patient is consistently cultures positive for pseudomonas (Mogayzel et al., 
2013). As adults, patients with CF are typically placed on a regimen of cyclical nebulized 
antibiotics twice a day after CPT. This lengthens the time of treatment to two hours total per day, 
one hour for each session. 
As CF symptoms worsen, oxygen supplementation and lung transplants are sometimes 
necessary. Oxygen therapy is recommended when CF patients develop hypoxemia, or oxygen 
deficiency in arterial blood (Elphick & Mallory, 2013). Lung transplantation is a decision made 
by the CF patients and his or her medical team when severe lung disease develops, often after 
oxygen therapy has been prescribed (CFF, 2013). Approximately 150-200 CF patients have 
received lung transplants in the past year. Over 80% of transplant recipients survive one year 
after transplantation, and over 50% are alive five years after transplantation (CFF, 2013). 
Gastrointestinal and nutritional therapies. Patients with CF require a high-fat, high-
calorie diet (Wolfe & Collins, 2007). Consuming additional calories and high-fat foods can cause 
conflict for patients and families that may inherently believe high-fat foods should be eaten in 
moderation, and need to adjust these beliefs to fulfill their nutrition needs. If conventional foods 
are not enough, boosting foods, such as heavy cream or butter, can be used; high-calorie 
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supplements are also encouraged, although they can be expensive (Bush, 2001). Vitamin 
supplementation is a final recommendation for nutritional balance in CF patients (Stallings et al., 
2008). Patients with CF need extra vitamins and minerals to combat the decreased absorption 
due to excess mucus. Commonly prescribed supplements include: Vitamins A, D, E, and K, and 
Calcium, Iron, salt, and Zinc (CFF, 2013). 
The second portion of the gastrointestinal regimen is pancreatic enzyme capsules, 
although these are not required for a portion of CF patients (CFF, 2013). These must be taken 
with most foods eaten, including snacks. If enzymes are not taken, patients with CF may 
experience malabsorption of fat or distal intestinal obstruction syndrome (DIOS; blockage of the 
intestines by thickened stool). Treatment of DIOS includes oral or rectal medications (Koletzko, 
Stringer, Cleghorn, & Durie, 1989; O’Halloran, Gilbert, McKendrick, Carty, & Heaf, 1986). 
If therapies are being followed and malnutrition remains a problem, overnight feedings 
with nasal or gastronomy tubes may be used (Levy, Durie, Pencharz, & Corey, 1985). These can 
provide up to 1000 calories per night through elemental compounds or whole proteins (again 
necessitating the use of pancreatic enzymes during the infusion). 
Other therapies. Development of liver disease and/or diabetes is common in patients 
with CF (Dondos & Westaby, 2007). Ursodeoxycholic acid and taurine to prevent bilary stasis 
are frequently used, and endoscopic sclerotherapy are employed if bleeding varices develop. 
Liver transplantation is used for end-stage disease. If diabetes is developed, frequent blood 
glucose testing, oral medications, and multiple subcutaneous insulin injections must be added to 
the existing CF regimen (Dondos & Westaby, 2007). 
CF adherence. Adherence rates in chronic illnesses, especially CF, are notoriously low. 
The CF regimen is complex, time consuming, and at times unpleasant. Research indicates that as 
patients with CF age, rates of adherence decline (Masterson, Wildman, Newberry, & Omlor, 
2011; Quittner et al., in press). Estimates of adherence in adults with CF range from 31-79% 
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(Burrows, Bunting, Masel, & Bell, 2002; Eakin, Bilderback, Boyle, Mogayzel, & Riekert, 2011; 
Elkins et al., 2006; Quittner et al., in press; Riekert, Boyle, & Rand, 2004; White, Morton, 
Peckham, & Conway, 2004), which is concerning as lower adherence to treatments is 
consistently linked to worse health outcomes (Quittner et al., 2014). Low adherence in adults has 
been attributed to increased treatment complexity, transfer of care from pediatrician to adult 
pulmonologist, and lack of visible benefit from treatments (Kettler, Sawyer, Winefield, & 
Greville, 2002). A study by George and colleagues (2010) interviewed adults with CF about 
perceived barriers to adherence. Reasons cited for nonadherence included: treatment burden 
(64%), social demands (60%), work demands (60%), forgetting (60%), absence of perceived 
health benefit (56%), fatigue (56%), and stigma/embarrassment (36%). 
 CPT is the least followed aspect of the regimen, perhaps because it is uncomfortable and 
time intensive (Arias Llorente, Bousoño Garcia, & Díaz Martín, 2008; Myers & Horn, 2006). It 
involves wearing a vest that deflates and inflates, applying pressure and vibration for 20-30 
minutes, two to four times per day. These sessions are often followed by the use of a nebulizer 
delivering antibiotics (CFF, 2013). Adherence rates for this therapy are quite low, and the lowest 
rates are seen in adults with CF. This is likely because adults are solely responsible for their 
regimen, and do not have parents or caregivers monitoring their daily treatment. Additionally, 
adherence to CPT does not provide noticeable short-term benefits, and stopping CPT for short 
periods may not result in evident declines (Myers, 2009). However, adherence to the respiratory 
regimen is important because CPT helps prevent infections and improve breathing (CFF, 2013). 
 Nutrition is another difficult to follow part of the medical regimen for patients with CF. 
Children and adults with CF do not consume as many calories, or calories from fat, as 
recommended (Arias Llorente et al., 2008). Many adults with CF are also unable to ingest 
sufficient calories due to CF side effects (e.g., infection-relation appetite loss, abdominal pain, 
gastroesophageal reflux). Adolescents with CF are at increased risk for developing eating 
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disorders, or disordered eating behaviors (Pumariega, Pursell, Spock, & Jones, 1986; Shearer & 
Bryon, 2004; Simon et al., 2011). Nutritional adherence is important because body weight in 
individuals with CF is consistently identified in the literature as a strong predictor of 
complications and disease severity (Beker, Russek-Cohen, & Fink, 2001; Sharma et al., 2000; 
Stern, Wiedemann, & Wenzlaff, 2008). 
The link between adherence and disclosure in CF remains largely unexplored. Research 
in HIV/AIDs and inflammatory bowel disease indicates that illness disclosure is related to 
greater adherence to medical regimens (Burstein, Taft, & Keefer, 2011; Mellins et al., 2002; 
Skhosana, Struthers, Gray, & McIntyre, 2006; Stirratt et al., 2006). On the other hand, research 
in CF indicates that disclosure has a complex association with adherence, with CF patients 
describing it as a facilitator and/or a barrier to adherence (Rand-Giovannetti, Eakin, George, 
Borrelli, & Riekert, 2010). Beyond validation of the CFDS, the proposed study also focused on 
understanding the association between disclosure and adherence in a sample of adolescents and 
young adults with CF. 
CF Disclosure 
As detailed in the general disclosure section above, the decision to disclose illness status 
has been evaluated in multiple health conditions. Results indicate that disclosure is consistently 
linked to social support (Beals et al., 2009; Gignac & Cao, 2009; Major et al., 1990; Merin & 
Pachankis, 2011), and decisions to disclose often vary based on the type of relationship with the 
non-discloser, the discloser’s level of education, and their perception of stigma surrounding their 
condition (Dyson et al., 2010). Studies in CF focused on illness disclosure provide mostly 
qualitative information derived from small sample sizes. A summary of disclosure-focused 
research conducted in CF is provided below, followed by a discussion of the importance of 
disclosure for CF patients. 
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Factors associated with disclosure in CF. Lowton (2004) conducted interviews with 
adults with CF regarding their disclosure to others and identified three categories of “telling 
situations,” categorized as low-, medium-, and high-risk. The author defined a low-risk situation 
as one with a short period of social interaction where the adult with CF has a low level of 
intimacy with the other person in the interaction. An example of this could be the checkout line 
at a grocery store. A medium-risk situation involves a higher level of intimacy where the 
perceived reaction of the non-CF adults begins to influence the decision to disclose. An example 
of this could be lunch with a friend. A high-risk situation includes settings where the 
consequences of disclosing CF are significant (e.g., the workplace). Perceived social support and 
disease severity were seen to influence disclosure decisions in this sample, such that higher 
levels of social support and more severe CF were related to more disclosure. In the current study, 
social support and disease severity were considered as correlates of the CFDS in validation 
analyses. 
In a large survey of adults with CF, respondents indicated they were more likely to 
disclose illness status to relatives (94%) and close friends (81%) than to dating partners (73%), 
bosses (51%), or co-workers (39%; Modi, Quittner, & Boyle, 2010). Additionally, women were 
more likely to disclose illness status than men. Participants with more severe CF were more 
likely to disclose to co-workers and bosses/supervisors/teachers, likely due to visibility of 
symptoms (e.g., weight loss, persistent cough). Overall, disclosing was described as neutral or 
positive, but negative interactions were more frequently reported with dating partners or bosses. 
By gaining more information about disclosure processes in CF, providers can hold an informed 
dialogue with CF patients about telling others and expectations associated with that experience. 
One study used a social psychology format to explore effects of disclosure in CF. Berlin 
and colleagues (2005) provided 391 young adults without CF with vignettes centered on a 
lunchtime interaction depicting concerns of an adult with CF about gaining weight and taking 
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enzymes before eating. These vignettes varied in a 2x2 design (male vs. female; preventative 
disclosure of disorder vs. nondisclosure). Participants were also administered demographic and 
psychosocial questionnaires. Authors discovered that disclosure of CF reduced participants’ 
perceptions of abnormal behavior or an eating disorder in those with CF, and assuaged 
respondents’ worries about the person with CF. This study highlights the benefits of disclosure in 
regard to stigma and negative perceptions held by others. 
Ravert & Crowell (2008) used a web-based search engine to identify web pages with CF 
disclosure content. Authors identified five categories that describe the purpose of the web page: 
information (i.e., page intended to inform public about CF), support (i.e., page intended to 
facilitate psychological support for patients with CF), social presentation (i.e., page encouraged 
individuals to create profiles and present personal beliefs), awareness/advocacy (i.e., page 
intended to solicit CF-specific action from visitors), and outreach (i.e., page created by an 
individual with CF to contact others with CF). CF disclosure topics were also grouped into 
categories: medical (e.g., discuss hospitalization due to CF), psychosocial concerns (e.g., 
concerns about CF and romantic relationships), supportive connection (e.g., disclosing CF in 
order to provide support to another with CF), positive framing (i.e., claiming that CF has a 
negligible impact on them), characteristic of self (i.e., CF used as one descriptor of many), and 
seeking resources (e.g., fundraising request). Adolescents most frequently expressed 
psychosocial concerns and enlisted social support, emerging adults tended to minimize CF as 
part of their identity, and adults tended to reach out to support others with CF. These age 
differences may be partially confounded by increased illness severity. Based on this study, it 
seems that important differences emerge with regard to age and illness severity in CF patients. 
Thus, analyses in this study were grouped by age and illness severity, as supported by other 
research as well. 
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Importance of disclosure in CF. Despite the number of symptoms children and 
adolescents with CF may experience, children and adolescents may attempt to hide their CF 
diagnosis and symptoms in order to appear “normal” to their peers (Christian & D’Auria, 1997). 
Additionally, children and adolescents may not always have control over to whom they disclose, 
as parents often decide whom to tell (e.g., teachers, religious leaders). In adulthood, CF patients 
have much more control over disclosure, and can decide whom and how much to tell about their 
diagnosis. Adults with CF find that some situations mandate CF disclosure (Lowton, 2004), such 
as when one has to miss work due to a CF exacerbation, or when a couple is planning to have 
children and require genetic or fertility testing. If a CF patient refuses to disclose his or her CF 
status, it can inhibit access to social support, which may negatively affect psychological 
functioning and health-related quality of life. Little is known, however, as to how CF patients 
handle these disclosure situations with family, friends, and coworkers. 
Beyond social ramifications, research indicates a relationship exists between disclosure 
and adherence in CF. A study by George and colleagues (2010) revealed that stigma or 
embarrassment associated with CF hindered adherence, while social support improved 
adherence. Examining disclosure, and social support gained as a result of it, could shed more 
light on factors impacting adherence in adulthood. Patients with CF may feel that if others know 
about their diagnosis, they may “bug” them to do therapies. Conversely, if people do not know 
someone’s CF diagnosis, the person with CF could feel uncomfortable doing therapies in front of 
them. In a qualitative study examining diabetes in the workplace, participants reported not 
managing their diabetes at work because they feared being stigmatized or treated negatively 
(Ruston, Smith, & Fernando, 2013); similar feelings may be present in adolescents and young 
adults with CF. Learning more about disclosure in this group of CF patients could help design 
better interventions to increase adherence. In general, validation of the CFDS and discovery of 
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associated psychosocial constructs helps explain how disclosure operates in adolescents and 
young adults with CF and processes that may promote or minimize disclosure. 
CF Disclosure Scale 
The CF Disclosure Scale (CFDS) was developed by researchers at Johns Hopkins 
University based on a pilot study investigating barriers and facilitators of treatment adherence in 
CF (George et al., 2010; Rand-Giovannetti et al., 2010). In the pilot study, semi-structured 
interviews were conducted with 25 adolescents and young adults with CF. Interviews followed a 
naturalistic inquiry format, and were transcribed verbatim after the interview. The average length 
of interview was approximately 45 minutes. After a set of five interviews was transcribed, the 
interviews were analyzed by principal investigators for common themes. Particular themes 
identified as necessitating further investigation were pursued in subsequent interviews. Only 
themes uniformly endorsed by participants were retained. 
Disease disclosure and the level of comfort doing therapy in front of others were named 
as both barriers and facilitators of adherence. Seventy-six percent of participants reported 
disclosing to friends, 56% reported not disclosing to casual acquaintances, and 52% reported 
disclosing to romantic partners. Participants varied in whether they felt comfortable doing 
treatments in front of people: 68% indicated they perform treatments in front of those who know 
their CF diagnosis, 44% reported they would perform fewer or no treatments in front of people 
who do not know their CF diagnosis, and 32% reported they would not perform treatments in 
front of some people who know their CF diagnosis (Rand-Giovannetti et al., 2010). This 
information was used to develop the CFDS. 
In creating the CFDS, authors also referenced existing HIV and CF disclosure literature 
(Admi, 1995; Berlin et al., 2005; Klitzman et al., 2004; Lowton, 2004; Stirratt et al., 2006). 
Based on these studies, it was determined that the most pertinent disclosure information to gather 
was: who people tell, how comfortable they feel telling, and whether they do their treatments in 
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front of these people. With these questions the CFDS captures a currently missing piece of the 
literature. Prior research has gathered information regarding who people tell and the outcomes of 
disclosure, but little is known about how comfortable CF patients feel disclosing to certain 
people and whether they perform CF treatments in front of certain people. 
The CFDS is a 21-item measure that assesses CF patients’ level of and comfort with 
disclosure of CF diagnosis to others (developed by Riekert and colleagues, 2010). Questionnaire 
sections include Friends, Spouse/Romantic Partner, Workplace, and School. In each section, 
respondents are first asked whether people in the section know that they have CF. Response 
options include “No”, “Yes, some”, and “Yes, all”. If they respond “No”, they move on to the 
next section. If they respond “Yes”, they are subsequently asked to rate their overall comfort in 
(1) discussing CF with people (e.g., Boss) in those settings (e.g., Workplace) and (2) doing CF 
treatments in front of people in those sections. Comfort in discussion and treatments are rated on 
a Likert scale (1 = Not at all comfortable, 10 = Completely comfortable). 
Given the items included in the CFDS and their organization, we believe that there are 
three potential ways to group the items into subscales: Group, Type of Disclosure, and People. 
Group Subscales includes subscales of Friends, Romantic Partner, Workplace, and School 
when appropriate as some participants may not be working or in school. Type of Disclosure 
Subscales includes subscales of People Told, Comfort in Discussion, and Comfort in Treatments. 
People Subscales includes more specific subscales of Close Friends, Casual Friends, Romantic 
Partner, Boss, Coworkers, Teachers, and Classmates when appropriate as some participants may 
not be working or in school. If an area does not apply to a participant, their data was coded as 
“missing” for that section. These subscales will allow examination of responses grouped by 
different environments (broad and specific), and responses grouped by comfort in discussion and 
comfort in treatments. By viewing responses in this manner, it can be determined whether 
 
 
17 
environments or disclosure types better capture disclosure in a CF sample. Subscale allocation is 
depicted below in Table 1; the CFDS itself can be located in the Appendices. 
Table 1. 
 
Subscales of the CFDS   
Subscale Grouping Subscales Item Numbers 
Group Subscales Friends 237-242 
 Romantic Partner 243-245 
 Workplace 246-251 
 School 252-257 
Type of Disclosure 
Subscales 
People Told 237, 240, 243, 246, 249, 252, 255 
 Comfort in Discussion 238, 241, 244, 247, 250, 253, 256 
 Comfort in Treatments 239, 242, 245, 248, 251, 254, 257 
People Subscales Close Friends 237-239 
 Casual Friends 240-242 
 Romantic Partner 243-245 
 Boss 246-248 
 Coworkers 249-251 
 Teachers 252-254 
 Classmates 255-257 
 
 Finally, in this project, two coding methods were piloted for the CFDS: Count and 
Cumulative Risk. A participant must answer “yes” to whether they disclosed to be included in 
count coding, otherwise their score is zero. Count coding sums and subsequently averages 
responses for discussion and treatment question to obtain subscale scores; then the average of all 
pertinent subscale scores is used to obtain an Overall Disclosure score. Based on the subscale 
method, Overall Disclosure scores can range from 0-10. We also coded the data using a 
cumulative risk coding technique to reflect that disclosure does not occur in isolation (Everhart, 
Fiese, & Smyth, 2008). Research supporting this coding method can be found below in the 
Psychometric Indices section. In this coding method, data were reverse scored for all questions 
about comfort discussing CF with others and comfort doing treatments in front of others (1 
became 10 and 10 became 1). Participants who have higher risk (less comfort in discussing, do 
not complete treatments in front of others) have higher scores to reflect their higher level of risk. 
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The cumulative risk calculation was subsequently adjusted to complement the reverse scoring. 
Participants who disclosed to no one received discussion and treatment scores of 21, as they are 
the most at risk and thus needed a value which reflected that. Twenty-one is essentially an 
arbitrary value, but it needs to be higher than any participant who disclosed to some could obtain 
(which is 20). This strategy was used only in environments which were applicable for 
participants. This technique is displayed below in Figure 3 as a formula. 
 
Disclosed to none: comfort in discussion and comfort in treatment score is automatically 21 
Disclosed to some (high score 20): [(2*comfort in discussion) + (2*comfort in treatment)] / 2  
Disclosed to all (high score 10): (comfort in discussion + comfort in treatment) / 2  
Figure 3. Cumulative risk coding method for the CFDS. 
 
Psychometric Indices 
The main focus of the proposed study was to evaluate the reliability and validity of the 
CFDS. We evaluated the reliability (e.g., internal consistency), convergent validity, and 
discriminant validity generated from each of the described subscale grouping and coding 
techniques. Multiple indices can be used to determine whether a measure adequately assesses a 
construct of interest (Kazdin, 2003). Reliability and validity evidence of a measure are the two 
main psychometric characteristics of measurement tools (Kazdin, 2003). Reliability refers to the 
consistency of a measure, while validity refers to whether the measure truly assesses a particular 
construct (Kazdin, 2003). Our discussion of psychometric properties includes a summary of 
cumulative risk scoring research and a description of pertinent internal consistency and validity 
techniques. 
Cumulative Risk Models 
 To date, there has been limited research regarding the cumulative processes that may 
influence disclosure (or nondisclosure) of a chronic illness. Cumulative risk research suggests 
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that as the number of risk factors increases, functioning on a particular outcome is negatively 
impacted (Sameroff, Seifer, Baldwin, & Baldwin, 1993). Cumulative risk aims to capture the 
additive nature of risk by considering the accumulation of risk factors. Cumulative risk has been 
examined in the areas of child development (Evans & English, 2002; Jones, Forehand, Brody, & 
Armistead, 2002), caregiver quality of life in pediatric asthma (Everhart et al., 2008), quality of 
life in pediatric inflammatory bowel disease (Gumidyala & Greenley, 2014). In the context of 
disclosure, cumulative risk coding provides a mechanism to account for not only whether a 
person discloses or not, but also to whom and how comfortable the person was with that 
disclosure. Associations between a cumulative coding method and CF outcomes (such as 
adherence) might suggest that more than just the act of disclosing is impacting processes related 
to disclosure; therefore, cumulative risk coding may be a more accurate representation of these 
associations. 
Internal Consistency 
Internal consistency refers to the distribution and homogeneity of the items within a 
scale. Methods by which to assess internal consistency include split half reliability, Kudar 
Richardson 20 formula, and Cronbach’s alpha (Kazdin, 2003). Cronbach’s alpha is the most 
commonly used calculation (Garson, 2010). An alpha of zero indicates that only error is being 
measured. An alpha of one indicates all items measure the true score (Garson, 2010). By 
convention, a cutoff of .60 is considered “lenient”, with .70 considered “adequate” and .80 is 
considered “good” internal consistency (Garson, 2010). As the number of questions increases, 
Cronbach’s alpha increases, meaning that shorter measures usually have lower alpha levels 
(Garson, 2010). In this study, we used Cronbach’s alpha to determine the internal consistency of 
subscales for each scoring method.  
Factor Analysis 
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Factor analysis is used to study relations among variables in a measure and determine 
which items best describe the factor being measured (e.g., which items “hang together”). Factor 
analysis requires multiple steps (DeVellis, 2012). First, a correlation matrix must be computed 
with all individual items in the measure, to determine covariance among items. Next, an item 
total is computed by summing all items, which allows computation of correlations between 
individual items and the latent variable being measured, represented by the item total. Through 
these correlations, groups of items, called factors, can emerge as measuring specific components 
of the latent variable. Two methods which are used to determine when enough factors have been 
extracted are Eigenvalues and scree tests. Eigenvalues are defined as representing the amount of 
information captured by a factor. Scree tests use the relative Eigenvalue rather than the absolute 
Eigenvalue, based on the number of questions and factors that emerge from the measure. 
Eigenvalues are numeric values, while scree tests generate a scree plot, which graphically depicts 
the value of each factor. Eigenvalues and scree tests were used to confirm projected subscales for 
all subscale grouping methods in this study. Factor analysis was only used when appropriate (i.e., 
with non-dichotomous variables). 
Validation 
 Known groups validation. To assess construct validity, this study used a method called 
known groups validity. Adequate known groups validity demonstrates that a scale can 
differentiate members of one group from another based on the score obtained on that scale 
(DeVellis, 2012). T-tests or ANOVAs are commonly used to determine whether groups are 
significantly different from one another based on the grouping factors of choice (DeVellis, 
2003). Gender, illness severity, and regimen complexity were used to group responses and 
determine whether disclosure differed significantly between these groups. Prior research 
indicates that disclosure differs based on gender and illness severity (Lowton, 2004; Ravert & 
Crowell, 2008; Admi, 1995; Modi et al., 2010). No research has examined disclosure and 
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regimen complexity, but considering the correlation between illness severity and regimen 
complexity (Eakin et al., 2011), we hypothesized that disclosure likely varied by regimen 
complexity. 
Convergent validity. Convergent validity is the level of agreement between two 
measures of the same construct (Kazdin, 2003). Typically, similar measures have moderate to 
high convergent validity such as subscales of the Cystic Fibrosis Questionnaire-Revised and the 
Short Form-36 Health Questionnaire (r = .57 - .84; Quittner, Buu, Messer, Modi, & Watrous, 
2005). If the measures converge, it provides evidence that the tools assess theoretically related 
constructs (Kazdin, 2003). Different formats that use varying administration modalities are 
recommended to avoid “source error” effects (Kazdin, 2003). Correlations above .40 indicate 
“good” convergent validity (Kazdin, 2003). 
Based on previous research, measures assessing social support, depression, quality of life, 
symptom difficulties, self-efficacy, and adherence were used in analyses of convergent validity 
for this study. For example, Gignac and Cao (2009) found that people with arthritis self-
disclosed to co-workers when they perceived a high level of social support. In a group 
counseling study for pregnant women with HIV, it was found that depression symptoms 
improved with disclosure (Kaaya et al., 2013). While no research has explicitly examined the 
link between quality of life and disclosure, it stands to reason that increased social support 
associated with disclosure will be related to improved quality of life. Symptom difficulties are 
related to disclosure because as CF worsens, symptoms become harder to mask; this necessitates 
disclosure in areas where the person may otherwise have hidden their diagnosis (Lowton, 2004; 
Modi et al., 2010). We postulated that questions regarding self-efficacy of doing treatments in 
front of others would be related to the CFDS, as previous research indicates that adults with CF 
consider doing treatments in front of others a type of disclosure (Rand-Giovannetti et al., 2010). 
Finally, we hypothesized that measures of adherence would correlate with the CFDS, as research 
 
 
22 
in HIV has established a link between disclosure and adherence (Burstein et al., 2011; Mellins et 
al., 2002; Skhosana et al., 2006; Stirratt et al., 2006). 
Discriminant validity. Discriminant validity tests whether concepts that are supposed to 
be unrelated, actually are unrelated (Kazdin, 2003). A successful discriminant validity result 
shows that a measure of one construct is not highly correlated with other measures of different 
concepts. A non significant correlation indicates acceptable discriminant validity. A lower 
correlation indicates that the measures are assessing different constructs, and strengthens the 
validity of the scale being evaluated (John & Benet-Martinez, 2000). CF knowledge will be used 
as a measure of discriminant validity against the CFDS. CF knowledge has been linked to patient 
age, gender, educational level (Nolan, Desmond, Herlich, & Hardy, 1985). However, there is no 
research linking CF knowledge to disclosure. Furthermore, adherence, which is hypothesized to 
relate to disclosure, is not related to CF knowledge (Conway, Pond, Hamnett, & Watson, 1996; 
Modi & Quittner, 2006). It was not expected that the amount of knowledge a patient possesses 
about CF would impact his or her decision to disclose to others. 
Insurance status also served as a measure of discriminant validity for the CFDS. There is 
no evidence that insurance status is linked to disclosure; further, socioeconomic status (SES), 
which is highly correlated with insurance status, has no relation to disclosure. 
Statement of Problem 
 The overarching goal of this study and its hypotheses was to evaluate a newly developed 
and piloted assessment of illness disclosure in CF, the CF Disclosure Scale (CFDS), which takes 
into account both diagnosis disclosure and level of comfort in doing treatments in front of others. 
Although general and disease-specific disclosure scales exist in other conditions, such as 
pediatric chronic pain (Jacobson et al., 2013), no study to date has evaluated a CF-specific 
disclosure measure. The present study determined the scoring and validity of the CFDS via 
evaluation of multiple subscale grouping and coding methods. Through this process, 
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psychosocial correlates that are associated with disclosure in CF were also revealed. Results 
provided novel information regarding disclosure that may help direct clinical care and research 
in CF. 
 The current study had five main aims. First, the CFDS data were grouped into three 
subscales: Group, Type of Disclosure, and People. Subsequently, the data were coded using the 
Count and Cumulative Risk methods previously discussed. 
 The second aim of this study was to then establish the psychometric properties of the 
illness disclosure measure. The internal consistency of the measure (Cronbach’s alpha) was 
computed for the overall score and the subscale scores of each subscale grouping method. 
Known groups validation was also completed for the subscales of each subscale grouping 
method, based on gender, a partial regimen complexity score (i.e., 1, 2, or 3; Sawicki et al., 
2013), and disease severity (i.e., mild, moderate, and severe; Fiel, FitzSimmons, & Schidlow, 
1994; DeVellis, 2012). T-tests were used for gender grouping, and ANOVAs were used for 
regimen complexity and disease severity grouping. Factor analysis were subsequently used to 
confirm hypothesized subscales for each subscale grouping method. Collinearity among the three 
subscale grouping methods was examined using a correlation matrix. 
 The third aim of this study was to conduct individual validity analyses for each subscale 
grouping method. Convergent and discriminant validity were assessed using correlations 
conducted between subscales and separate measures administered to participants. These are 
detailed in Table 2 in the hypotheses below. 
 Information gathered from aims one, two, and three were used in aim four to determine 
the best subscale grouping method for the CF Disclosure Scale. Measures of internal consistency 
were the bulk of this aim, with factor analysis used when appropriate. Descriptive statistics and 
validity results were also examined to determine the best subscale grouping method. 
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 The fifth and final aim was the determination of the best coding method for the CFDS.  
Information gleaned from aims one through four was used to compare and judge the two coding 
methods according to criteria specified under Research Aim 5 in the next section. 
Research Aims and Hypotheses 
 Research aim 1. To score the CF Disclosure Scale according to the three subscale 
grouping methods (e.g., Group, Type of Disclosure, and People) and two coding techniques 
(Count and Cumulative Risk). 
 Research aim 2. Establish psychometric properties of three subscale grouping methods 
for the CF Disclosure Scale.  
Hypothesis 2a. Using known groups validation, female participants will score higher on 
all subscales of each subscale grouping method, indicating higher levels of, and comfort in, 
disclosure. 
Hypothesis 2b. Using known groups validation, participants with more severe CF who 
are currently working or in school will score higher on all pertinent subscales of Group and 
People subscale grouping methods due to the visibility of symptoms. 
Hypothesis 2c. Using known groups validation, participants who have more complex CF 
regimens who are currently working or in school will score higher on all pertinent subscales of 
Group and People subscale grouping methods due to the number of treatments and time needs of 
the regimen. 
Research aim 3. To determine convergent and discriminant validity of the three subscale 
grouping and two coding methods of the CF Disclosure Scale. 
Hypotheses 3a-3v. Subhypotheses are displayed below in Table 2. 
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Table 2. 
 
Hypotheses 3a-3aj 
  
Scoring Method Convergent Validity Discriminant Validity 
Count Group 
Subscale 
Friends and Romantic Partner 
subscales, and Overall Disclosure 
Score will be significantly positively 
associated with the Medical 
Outcome Study Social Support 
Survey (3a) 
 
All subscales and Overall 
Disclosure Score will be 
significantly positively associated 
with the Emotional Functioning and 
Social Functioning subscales of the 
Cystic Fibrosis Questionnaire- 
Revised (3b) 
 
All subscales and Overall 
Disclosure Score will be 
significantly positively associated 
with the Respiratory and Digestive 
Symptoms subscales of the Cystic 
Fibrosis Questionnaire–Revised 
(3c) 
 
All subscales and Overall 
Disclosure Score will be 
significantly negatively associated 
with the Center for Epidemiologic 
Studies Depression Scale (3d) 
 
All subscales and Overall 
Disclosure Score will be 
significantly positively associated 
with the Composite Medication 
Possession Ratio (3e) 
 
 
 
 
 
 
 
 
 
 
All subscales and Overall 
Disclosure Score will not 
significantly correlate with the 
CF Knowledge Questionnaire 
(3f) 
 
All subscales and Overall 
Disclosure Score will not 
significantly correlate with 
insurance status (3g) 
Table 2 continues 
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Table 2 continued 
Type of Disclosure 
Subscale 
People Told and Comfort in 
Discussion subscales, and Overall 
Disclosure Score will be 
significantly positively associated 
with the Medical Outcome Study 
Social Support Survey. (3h) 
 
Comfort in Treatments subscale 
will be significantly positively 
associated with the Self-Efficacy 
Questionnaire (3i) 
 
All subscales and Overall 
Disclosure Score will be 
significantly positively associated 
with the Emotional Functioning and 
Social Functioning subscales of the 
Cystic Fibrosis Questionnaire- 
Revised (3j) 
 
People Told subscale will be 
significantly positively associated 
with the Respiratory and Digestive 
Symptoms subscales of the Cystic 
Fibrosis Questionnaire- Revised 
(3k) 
 
All subscales and Overall 
Disclosure Score will be 
significantly negatively associated 
with the Center for Epidemiologic 
Studies Depression Scale (3l) 
 
All subscales and Overall 
Disclosure Score will be 
significantly positively associated 
with the Composite Medication 
Possession Ratio (3m) 
 
 
 
 
 
 
 
 
 
All subscales and Overall 
Disclosure Score will not 
significantly correlate with the 
CF Knowledge Questionnaire 
(3n) 
 
All subscales and Overall 
Disclosure Score will not 
significantly correlate with 
insurance status (3o) 
Table 2 continues 
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Table 2 continued 
Count People 
Subscale 
Close Friends and Romantic 
Partner subscales, and Overall 
Disclosure Score will be 
significantly positively associated 
with the Medical Outcome Study 
Social Support Survey (3p) 
 
All subscales and Overall 
Disclosure Score will be 
significantly positively associated 
with the Emotional Functioning and 
Social Functioning subscales of the 
Cystic Fibrosis Questionnaire- 
Revised (3q) 
 
All subscales and Overall 
Disclosure Score will be 
significantly positively associated 
with the Respiratory and Digestive 
Symptoms subscales of the Cystic 
Fibrosis Questionnaire- Revised 
(3r) 
 
All subscales and Overall 
Disclosure Score will be 
significantly negatively associated 
with the Center for Epidemiologic 
Studies Depression Scale (3s) 
 
All subscales and Overall 
Disclosure Score will be 
significantly positively associated 
with the Composite Medication 
Possession Ratio (3t) 
 
 
 
 
 
 
 
 
 
 
 
 
 
All subscales and Overall 
Disclosure Score will not 
significantly correlate with the 
CF Knowledge Questionnaire 
(3u) 
 
All subscales and Overall 
Disclosure Score will not 
significantly correlate with 
insurance status (3v) 
Table 2 continues 
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Table 2 continued 
Risk Group 
Subscale 
Friends and Romantic Partner 
subscales, and Overall Disclosure 
Score will be significantly 
negatively associated with the 
Medical Outcome Study Social 
Support Survey (3w) 
 
All subscales and Overall 
Disclosure Score will be 
significantly negatively associated 
with the Emotional Functioning and 
Social Functioning subscales of the 
Cystic Fibrosis Questionnaire- 
Revised (3x) 
 
All subscales and Overall 
Disclosure Score will be 
significantly negatively associated 
with the Respiratory and Digestive 
Symptoms subscales of the Cystic 
Fibrosis Questionnaire–Revised 
(3y) 
 
All subscales and Overall 
Disclosure Score will be 
significantly positively associated 
with the Center for Epidemiologic 
Studies Depression Scale (3z) 
 
All subscales and Overall 
Disclosure Score will be 
significantly negatively associated 
with the Composite Medication 
Possession Ratio (3aa) 
 
 
 
 
 
 
 
 
 
 
 
 
 
All subscales and Overall 
Disclosure Score will not 
significantly correlate with the 
CF Knowledge Questionnaire 
(3ab) 
 
All subscales and Overall 
Disclosure Score will not 
significantly correlate with 
insurance status (3ac) 
Table 2 continues 
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Table 2 continued 
Risk People 
Subscale 
Close Friends and Romantic 
Partner subscales, and Overall 
Disclosure Score will be 
significantly negatively associated 
with the Medical Outcome Study 
Social Support Survey (3ad) 
 
All subscales and Overall 
Disclosure Score will be 
significantly negatively associated 
with the Emotional Functioning and 
Social Functioning subscales of the 
Cystic Fibrosis Questionnaire- 
Revised (3ae) 
 
All subscales and Overall 
Disclosure Score will be 
significantly negatively associated 
with the Respiratory and Digestive 
Symptoms subscales of the Cystic 
Fibrosis Questionnaire- Revised 
(3af) 
 
All subscales and Overall 
Disclosure Score will be 
significantly positively associated 
with the Center for Epidemiologic 
Studies Depression Scale (3ag) 
 
All subscales and Overall 
Disclosure Score will be 
significantly negatively associated 
with the Composite Medication 
Possession Ratio (3ah) 
All subscales and Overall 
Disclosure Score will not 
significantly correlate with the 
CF Knowledge Questionnaire 
(3ai) 
 
All subscales and Overall 
Disclosure Score will not 
significantly correlate with 
insurance status (3aj) 
 
Research aim 4. To determine the best subscale grouping method for the CF Disclosure 
Scale. Given the exploratory nature of this aim, we did not have a specific hypothesis based on 
which subscale may emerge as the “best” method for the grouping the CF Disclosure Scale. We 
used results from Research Aims Two and Three to determine which method was “best” based 
on these criteria: 
1) Normal distribution of responses 
2) Eigenvalues above 1.0 
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3) Scree plots with significant values for postulated subscales 
4) Factor analysis methods will be used when appropriate (i.e., for non-dichotomous 
scales) 
5) Higher internal consistency (α ≥ 0.7) 
6) Acceptable convergent and discriminant validity 
Research aim 5. Based on prior research (Evans & English, 2002; Everhart et al., 2008; 
Gumidyala & Greenley, 2014; Jones et al., 2002), we expected Cumulative Risk Coding to 
emerge as a better indicator of disclosure. We used results from the above aims to determine 
which method was “best” based on these criteria: 
1) Normal distribution of responses 
2) Higher convergent validity values (effect size) 
3) Lower discriminant validity values (effect size) 
Method 
Participants 
 Participants included 128 people with CF ages 16 or older seen at the Johns Hopkins 
Cystic Fibrosis Center in Baltimore, Maryland. Data were utilized from a baseline assessment of 
a longitudinal randomized control trial comparing two interventions and their impact on 
adherence in adolescents and young adults with CF. Inclusion criteria required confirmed 
diagnosis of CF, age 16 years or older, scheduled upcoming clinic visit, clinical stability (e.g., 
not on intravenous medications for the previous 14 days), and prescription of inhaled mucolytic, 
inhaled antibiotic therapy, chronic macrolide therapy and/or hypertonic saline therapy for the last 
year. Exclusion criteria included Burkholderia cepacia complex isolated from the respiratory 
tract within the past two years, history of a lung transplant, or their participation in the pilot 
study on which the current study was based. Participants were majority 67 male (53.0%), with a 
mean age of 29 years (SD = 11.1), average FEV1 percent predicted value of 68.7 (SD = 23.3), 
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and mean partial regimen complexity scores of 8.8 (SD = 3.4). The sample was self-identified as 
93% Caucasian, 3% African American, 1% Latino, and 3% Other. Half of the sample had never been 
married, 38% were currently married, 9% of participants were with a partner, and 3% were divorced. 
Annual household incomes reported by the sample were evenly distributed across low, middle, and 
upper-class, and most participants had private health insurance (78%). Sample demographic 
characteristics are below in Table 3. 
Table 3. 
 
Sample Demographic Characteristics 
    n (%) 
Male 67 (53%) 
Female 60 (47%) 
Ethnicity:  Caucasian 119 (93%) 
                  African American 4 (3%) 
                   Latino 1 (1%) 
                   Other 4 (3%) 
Marital status: Single 64 (50%) 
                        Married 49 (38%) 
                        With a partner 11 (9%) 
                        Divorced 4 (3%) 
Household Income: <$25,000 10 (8%) 
$25,000-$49,999 4 (3%) 
$50,000-$74,999 10 (8%) 
$75,000-$99,999 13 (10%) 
$100,000-$124,999 9 (7%) 
$125,000-$149,999 3 (2%) 
<$150,000 16 (12%) 
Insurance status: Private 100 (78%) 
Public 19 (15%) 
Unknown 7 (5%) 
Public 2 (2%) 
Procedure 
 Potential participants and their parents or guardians (when applicable) received a 
recruitment letter for participation in a randomized clinical trial (RCT) targeting adherence in 
CF. This letter gave them the option to opt out of the study by emailing or phoning the study 
center. After the recruitment letter was sent, potential participants or their parents/guardians were 
contacted by telephone and invited to participate. Research assistants attempted to make first 
contact by phone; however, if the family was unable to be reached via telephone, they were 
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approached at their CF clinic visit and invited to participate. If participants (and 
parents/guardians, when applicable) agreed, written informed consent and assent were obtained. 
The participant completed baseline questionnaires at their subsequent, non-sick clinic visit and 
received $35. 
Measures 
 Cystic Fibrosis Disclosure Scale. See page 16 for the description of the Cystic Fibrosis 
Disclosure Scale (CFDS). 
Demographic information. Participant demographic information was obtained from 
questionnaires completed by the participant at their baseline evaluation. Information was 
gathered about participants’ date of birth, gender, ethnicity, educational level, and multiple 
indicators of SES (including insurance status). 
Disease severity. Disease severity was measured by FEV1 percent predicted at the time 
of a participant’s medical appointment. FEV1 is derived from the FEV1/FVC ratio, which is the 
maximum amount of air a person can expel from the lungs in the first second of exhalation after 
a maximum inhalation (Quanjer et al., 1993). FEV1 percent predicted is the FEV1/FVC ratio 
divided by the average FEV1/FVC ratio in the population for persons of similar age, gender, and 
body composition. Poorer lung function is indicated by lower FEV1 percent predicted values. 
FEV1 values were grouped as follows: ≥ 70% mild, 41-69% moderate, ≤ 40% severe (Fiel et al., 
1994). FEV1 percent predicted values were obtained by medical chart review. 
Adherence. CF medication adherence, a composite medication possession ratio (cMPR) 
was calculated based on participants’ medication refill data. Study staff obtained records from 
participants’ self-identified pharmacies for the previous year. A ratio was calculated for each 
prescribed pulmonary medication (maximum six medications: azithromycin, DNase, inhaled 
tobramycin, hypertonic saline, colistin, and/or aztreonam lysine) using the following procedure: 
the sum of all days of medication supply dispensed during the previous year, divided by the 
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number of days each medication was prescribed in the same interval. Because medications 
dispensed during hospitalizations are not captured in pharmacy records, the number of days 
hospitalized during the interval was subtracted from the denominator. Values were capped at 
100% and the ratios for each medication were averaged across all prescribed medications to 
determine a cMPR adherence score (Eakin et al., 2011). This cMPR provides an objective value 
representing the previous year’s adherence across all prescribed pulmonary medications. cMPR 
has been used in previous research and is an accepted objective measure of adherence (Quittner 
et al., in press). 
Regimen complexity. Participants’ regimens were grouped based on complexity using a 
method developed by Sawicki and colleagues (2013). Treatments are assigned a score, ranging 
from one to three, based on their difficulty to administer. Examples of treatment groupings are as 
follows: (1) inhaled bronchodilator, (2) pancreatic enzymes, and (3) insulin. Scores can range 
from 0-72, and treatments are categorized as “Respiratory” or “Other.” A sample of 3,096 adults 
with CF revealed the mean treatment difficulty to be 12.1, with an increase of 1.20 over the 
course of a three-year period (Sawicki et al., 2013). 
In this study, limited information was collected regarding medication regimens, such that 
investigators only recorded whether a participant was prescribed any of these six medications at 
baseline: azithromycin, aztreonam lysine, colistimethate, dornase alfa, hypertonic saline, and 
tobramycin. Chest physiotherapy was assumed to be prescribed for all participants. Only a partial 
regimen complexity score was able to be calculated due to this limited medication information 
available to researchers. The six medications recorded were grouped numerically as directed by 
Sawicki et al., summed, and averaged to obtain a partial mean treatment difficulty value. 
Medical Outcome Study Social Support Survey. The Medical Outcomes Study Social 
Support Survey (MOS-SS) is a 19-item, self-administered measure of functional social support 
for independently living chronically ill persons (Sherbourne, & Stewart, 1991). It was 
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administered to 2987 adult participants in the Medical Outcomes Study. Each question is 
preceded by the prompt “How often is each of the following kinds of support available to you if 
you need it?” The MOS-SS assesses four dimensions of social support: Emotional/Informational 
Support (e.g., “Someone to share your most private worries and fears with”), Tangible Support 
(e.g., “Someone to help you if you were confined to bed”), Positive Social Interaction (e.g., 
“Someone to have a good time with”), and Affectionate Support (e.g., “Someone who shows you 
love and affection”). Responses are rated on a Likert scale of 1 = none of the time to 4 = all of 
the time, and summed for an Overall Support Index. Previous analyses by Sherbourne & Stewart 
(1991) reveal high internal consistency (.91 or greater) and acceptable test-retest reliability (.72 
or greater) for all subscales. This measure can be found in the appendices at the end of this 
manuscript. 
Center for Epidemiological Studies- Depression scale. The Center for Epidemiological 
Studies- Depression scale (CES-D) is a twenty-item self-report scale designed to measure 
depressive symptomatology over the previous week (Radloff, 1977). Questions were developed 
based on major components of depressive symptomatology based on previous literature (i.e., 
depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, 
psychomotor retardation, loss of appetite, and sleep disturbance). In this study, each question is 
preceded by the prompt “For the following 20 items please select the choice that best describes 
how you have felt over the past week.” Example questions include “I felt lonely”, “I felt 
depressed”, and “I could not get going.” Responses are rated on a four-point Likert scale ranging 
from 0 = Rarely or none of the time [less than 1 day] to 3 = Most or all of the time [5-7 days], 
with total scores ranging from 0-60. Higher scores indicate more depressive symptoms. This 
survey was normed on a sample of 2514 members of the general population and 70 inpatient 
psychiatric patients. Based on analyses conducted by Radloff (1977), the CES-D displays high 
 
 
35 
internal consistency (.85 or greater) and adequate test-retest reliability (ranging between .45 and 
.70). This measure can be found in the appendices at the end of this manuscript. 
Cystic Fibrosis Questionnaire- Revised. The Cystic Fibrosis Questionnaire- Revised 
(CFQ-R) is a forty-four-item self-report scale that assesses health-related quality of life in 
adolescents and adults with CF (Quittner et al., 2005). This questionnaire was adapted from the 
original French version of the Cystic Fibrosis Questionnaire (Henry, Aussage, Grosskopf, & 
Goehrs, 2003). Questions address both general and CF-specific domains of health-related quality 
of life. Subscales include physical functioning, role functioning, vitality, health perceptions, 
emotional functioning, social functioning, body image, eating disturbances, treatment burden, 
and respiratory and digestive symptoms. Example questions include “During the past two weeks, 
indicate how often you felt worried”, “To what extent do your treatments make your daily life 
more difficult” and “During the past two weeks, have you had to cough up mucus?” Responses 
are rated on a variety of scales based on the question, either a Likert scale assessing 
frequency/difficulty, or binary true/false responses. Higher scores signify better quality of life. 
The CFQ-R was validated on a sample of 212 adolescents and adults with CF. Based on analyses 
conducted by Quittner and colleagues (2005), the CFQ-R displays high internal consistency 
(ranging between .67 and .94) and adequate test-retest reliability (ranging between .45 and .90). 
Convergent validity analyses conducted with the Short Form-36 Health Questionnaire (Ware & 
Sherbourne, 1992), a well-validated health-related quality of life measure, indicated good 
convergent validity as well (ranging between .57 and .84). This measure can be found in the 
appendices at the end of this manuscript. 
Self-Efficacy Questionnaire. The Self-Efficacy Questionnaire is a 19-item self-report 
measure of self-efficacy in CF-related tasks. It was developed using data from the pilot study 
referenced in the CFDS description. Following the pilot study, it was administered to adults with 
CF, with a parallel measure of self-efficacy, to evaluate its reliability and concurrent validity. 
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The cMPR of participants was used as a parallel measure against which to assess the Self-
Efficacy Questionnaire. Results indicated good convergent validity (α = 0.88; Riekert, Rand-
Giovannetti, Borrelli, Green, & Eakin, 2012). This measure can be found in the appendices at the 
end of this manuscript. 
CF Knowledge Questionnaire. The Cystic Fibrosis Knowledge Questionnaire (CFKQ) 
is a 36 item self-report measure that evaluates knowledge of disease management in several key 
areas for CF care: 1) lung health, 2) nutrition, 3) early signs of a pulmonary exacerbation, 4) 
maintenance and cleaning of equipment, and 5) the purpose of CF treatments. Two versions 
exist; one for school-age children and one for parents. The parent version was used for this study. 
This measure has yielded strong internal consistency coefficients (0.92; Modi & Quittner, 2006; 
Quittner, Drotar, Ievers-Landis, & Slocum, 2000). The CFKQ also has demonstrated 
convergence with measures of adherence and increased scores after provision of an education 
intervention (Quittner, Drotar, & Ievers-Landis, 2004). This measure can be found in the 
appendices at the end of this manuscript. 
Statistical Analyses 
 All analyses were performed using SPSS version 22.0 software ((Statistical 
Product and Service Solutions 22.0; SPSS Inc., Chicago, IL). Correlation matrices were 
generated with all individual items of the CFDS to determine collinearity. Data were 
subsequently grouped into Group, Type of Disclosure, and People Subscales and coded using 
Count and Cumulative Risk scoring techniques. Descriptive statistics for each scoring method 
were examined to determine ceiling and floor effects, variability, mean, medians, and other 
measures of central tendency (see Table 6). Correlations were generated to examine relations 
among the three scoring methods (see Tables 7 through 9). Cronbach’s alpha was computed for 
the overall score and the subscale scores of each subscale grouping method. T-tests and 
ANOVAs were used to determine known groups validity, splitting the data into groups by 
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gender, regimen complexity (i.e., 1, 2, and 3), and disease severity (i.e., mild, moderate, and 
severe) groups. Factor analysis was used with non-dichotomous data. Using the individual item 
correlation matrix, Eigenvalues and scree tests were generated when possible to confirm 
hypothesized subscales. Convergent validity was assessed with Pearson’s r correlation 
coefficient to determine the level of correlation between the CFDS and other measures. 
Discriminant validity was assessed with Pearson’s r correlation coefficient to determine the 
correlation between the CFDS and the CF Knowledge Questionnaire and insurance status. 
 A power analysis revealed that our sample of participants provided power statistics 
ranging from .05 to .84 for t-test analyses with independent groups. Only one power statistic 
exceeded .80. The wide range in values is due to the difference in sample size between 
groupings. For example, only 24 participants were included in analyses for school disclosure. For 
ANOVA analyses, the power statistic ranged from .16 to .69. Based on the benchmark power 
value of .80 or higher for all analyses (Cohen, 1992), these findings indicate that this study was 
underpowered to detect significant differences in almost all t-test and ANOVA analyses. 
Additional data including means and standard deviations have been provided to aid in 
interpretation of these findings. While missing data impacted the use of certain statistical 
methods and subsequent interpretation of those results, many other analyses (e.g., correlations) 
are able to be interpreted.  
Results 
 After descriptive information is presented, findings are discussed in order of study aims: 
(1) description of coding and grouping of CFDS questions, (2) psychometric properties of the 
three subscale grouping methods of the CFDS, (3) convergent and discriminant validity findings 
for the CFDS, (4) information regarding the “best” grouping method for the CFDS, and (5) 
information regarding the “best” coding method for the CFDS. For purposes of this study, “best” 
is defined as: normal distribution of responses, Eigenvalues above 1.0, scree plots with 
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significant values for postulated subscales, higher internal consistency (α ≥ 0.7), higher 
convergent validity values (effect size) and lower discriminant validity values (effect size). 
Sample disease care and psychosocial characteristics were gathered by the Cystic 
Fibrosis Questionnaire-Revised. These can be found in Table 4 below. 
 
Table 4. 
 
Sample Disease Care and Psychosocial Characteristics 
    M (SD)   Range 
Age 29.2 (11.1) 16.0-63.0 
FEV1 % predicted
a 68.7 (23.3) 20.0-134.0 
Body mass indexb 22.7 (3.8) 16.1-36.9 
Regimen complexityc 8.8 (3.4) 4.0-14.0 
MOS-SSd 60.4 (15.6) 0.0-76.0 
Emotional functioninge 73.5 (19.5) 0.0-100.0 
Social functioningf 70.2 (19.9) 16.7-100.0 
Respiratory symptomsg 64.8 (17.7) 16.7-100.0 
Digestive symptomsh 75.4 (19.2) 22.2-100.0 
Self-efficacyi 130.5 (37.5) 27.0-190.0 
CES-Dj 10.8 (9.3) 0.0-49.0 
Adherence 0.44 (0.27) 0.0-1.0 
CFKQk 23.7 (4.2) 5.0-32.0 
aFEV1 % predicted: higher values indicate better lung function. 
bBody mass index: higher values indicate higher (better) weight. cRegimen 
complexity: higher values indicate higher regimen complexity. dMOS-SS: higher values indicate more social support.  eEmotional functioning: 
higher scores indicate better emotional functioning. fSocial functioning: higher scores indicate better social functioning. gRespiratory symptoms: 
higher scores indicate fewer respiratory symptoms. hDigestive symptoms: higher scores indicate fewer digestive symptoms. iSelf-efficacy: higher 
scores indicate greater self-efficacy. jCES-D: Higher scores indicate more depressive symptoms. kCFKQ: Higher scores indicate greater 
knowledge of CF. 
 
The distribution of the raw, uncategorized data from the CFDS is presented in Table 5. This table 
gives percentages of CFDS responses categorized as: Missing; N/A; No; Yes, some; Yes, all; and 
Yes. A final column indicates the percentage of participants who provided a rating to the listed 
question, when applicable. 
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Table 5. 
 
Response Allocation for the CFDS 
Question Missing 
(%) 
N/A 
(%) 
No (%) Yes, 
Some (%) 
Yes, All 
(%) 
Yes (%) Provided 
Rating 
(%) 
1. Do your close friends 
know that you have CF? 
1 (0.8) --- 6 (4.7%) 31 
(24.2%) 
90 
(70.3%) 
--- 
 
--- 
2. Comfort in discussing 
your CF experience with 
your close friends. 
0 (0%) 6 (4.7%) --- --- --- --- 
 
122 
(95.3%) 
3. Comfort in doing 
your CF treatments in 
front of your close 
friends. 
0 (0%) 
 
6 (4.7%) --- --- 
 
--- --- 
 
122 
(95.3%) 
4. Do your casual 
friends know that you 
have CF? 
1 
(0.8%) 
--- 26 
(20.3%) 
79 
(61.7%) 
22 
(17.2%) 
--- 
 
--- 
5. Comfort in discussing 
your CF experience with 
your casual friends. 
--- 20 
(15.6%) 
--- --- --- --- 
 
108 
(84.4%) 
6. Comfort in doing 
your CF treatments in 
front of your casual 
friends. 
--- 19 
(14.8%) 
--- --- --- --- 
 
109 
(85.2%) 
7. Does your current 
romantic partner know 
that you have CF? 
1 
(0.8%) 
37 
(28.9%) 
3 (2.3%) --- 
 
--- 
 
87 (68%) 
 
--- 
8. Comfort in discussing 
your CF experience with 
your current romantic 
partner. 
1 
(0.8%) 
37 
(28.9%) 
--- --- --- --- 90 
(70.3%) 
9. Comfort in doing 
your CF treatments in 
front of your current 
romantic partner. 
2 
(1.6%) 
37 
(28.9%) 
--- --- --- --- 89 
(69.5%) 
10. Does your current 
boss know that you have 
CF? 
3 
(2.3%) 
32 (25%) 27 
(21.1%) 
--- --- 66 
(51.6%) 
--- 
11. Comfort in 
discussing your CF 
experience with your 
current boss. 
1 
(0.8%) 
59 
(47.2%) 
--- --- --- --- 68 
(53.1%) 
12. Comfort in doing 
your CF treatments in 
front of your current 
boss. 
1 
(0.8%) 
59 
(47.2%) 
--- --- --- --- 68 
(53.1%) 
13. Do your current 
coworkers know that 
you have CF? 
0 (0%) 32 (25%) 28 
(21.9%) 
45 
(35.2%) 
23 (18%) --- --- 
14. Comfort in 
discussing your CF 
experience with your 
current coworkers. 
 
 
 
0 (0%) 56 
(43.8%) 
--- --- --- --- 72 
(56.3%) 
Table 5 continues 
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Table 5 continued 
15. Comfort in doing 
your CF treatments in 
front of your current 
coworkers. 
0 (0%) 56 
(43.8%) 
--- --- --- --- 72 
(56.3%) 
16. Do your current 
teachers know that you 
have CF? 
2 
(1.6%) 
81 
(63.3%) 
20 
(15.6%) 
9 (7%) 16 
(12.5%) 
--- --- 
17. Comfort in 
discussing your CF 
experience with your 
current teachers. 
2 
(1.6%) 
100 
(76.5%) 
--- --- --- --- 28 
(21.9%) 
18. Comfort in doing 
your CF treatments in 
front of your current 
teachers. 
2 
(1.6%) 
100 
(76.5%) 
--- --- --- --- 28 
(21.9%) 
19. Do your current 
classmates know that 
you have CF? 
2 
(1.6%) 
81 
(63.3%) 
24 
(18.8%) 
17 
(13.3%) 
4 (3.1%) --- --- 
20. Comfort in 
discussing your CF 
experience with your 
current classmates. 
2 
(1.6%) 
101 
(78.9%) 
--- --- --- --- 25 
(19.5%) 
21. Comfort in doing 
your CF treatments in 
front of your current 
classmates. 
2 
(1.6%) 
101 
(78.9%) 
--- --- --- --- 25 
(19.5%) 
 
 
Aim 1 
 For count coding in People and Group subscales, responses for comfort in discussion and 
treatment were summed and divided by 2. The question “does X know about your CF” was 
recoded as follows: Missing –left blank; N/A – left blank; No – 0; Yes some – 1; Yes all – 2. 
Questions with only Yes, No, or N/A responses were recoded as follows: Missing – left blank; 
N/A – left blank; No – 0; Yes – 2. In this case, “yes” became 2 to reflect a complete level of 
disclosure indicated by 2 on other questions containing two levels of “yes” (some or all). Missing 
and N/A responses were left blank to remove those questions from analyses, as they did not 
pertain to disclosure levels. “No” was coded as zero to reflect the lowest level of disclosure. 
When “Yes some” and “yes all” were response options, they remained 1 and 2 respectively to 
reflect the graded nature of disclosure for those responses. For count coding in the Type 
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subscale, responses were summed and divided by the number of responses provided by the 
participant. 
Table 6. 
Descriptive Characteristics of the CFDS 
Coding & Subscale Type Range Median IQR M SD 
Count Overall (n=124) 0.5-10 4.5 2.75-6.42 4.66 2.29 
Count People      
Close Friends (n=122) 1-10 8.5 5.88-10 7.62 2.51 
Casual Friends (n=108) 1-10 5.25 3.5-7.5 5.69 2.87 
Romantic (n=89) 1-10 10 9.5-10 9.35 1.59 
Boss (n=68) 1-10 6.5 4-10 6.38 3.08 
Coworkers (n=72) 1-10 5.5 3.5-9 5.83 3.04 
Teachers (n=28) 1-10 6.0 4-8.88 6.20 2.58 
Classmates (n=25) 1.5-10 5.5 3.5-8 5.76 2.56 
Count Group      
Friends (n=124) 1-10 7.13 5-8.94 6.70 2.53 
Romantic (n=89) 1-10 10 9.5-10 9.35 1.59 
Workplace (n=79) 1-10 5.5 3.5-9 6.04 2.99 
School (n=30) 1-10 5.63 4-7.56 5.75 2.48 
Count Type of Disclosure      
People Told (n=126) 0-2 1.60 1.5-1.8 1.61 .289 
Comfort in Discussion (n=126) 2-10 8.18 6.15-9.43 7.55 2.20 
Comfort in Treatments 
(n=125) 
1-10 6.0 4.1-8.4 6.14 2.51 
Risk Overall (n=127) 1-21 7.67 4.38-
11.67 
8.14 4.89 
Risk People      
Close Friends (n=126) 1-21 3.5 1-7 5.50 5.76 
Casual Friends (n=126) 1-21 12 6.38-19 11.72 6.90 
Romantic (n=90) 1-21 1.0 1-1.63 2.21 3.74 
Boss (n=93) 1-21 6.5 2.5-21 9.27 7.95 
Coworkers (n=95) 1-21 14 4-21 12.51 7.59 
Teachers (n=45) 1-21 12 4.25-21 12.78 8.03 
Classmates (n=45) 1-21 21 10.5-21 15.66 6.93 
Risk Group      
Friends (n=127) 1-21 7.75 4-12.25 8.63 5.63 
Romantic (n=90) 1-21 1.0 1-1.63 2.21 3.74 
Workplace (n=96) 1-21 11 4.38-
17.88 
11.02 7.12 
School (n=46) 1-21 15.25 8.25-21 14.36 7.08 
 
 
Range, median, interquartile range, mean, and standard deviations for Count and 
Cumulative Risk subscales are presented above in Table 6. Participants who had not disclosed to 
 
 
42 
others were not included in these analyses or tables, as they did not report comfort in discussion 
or doing treatments in front of others. Participants disclosed to romantic partners and close 
friends most frequently, and casual friends and classmates least frequently. These findings are 
consistent across all coding and subscale strategies. Count coding showed a wider variation in 
the level of Workplace disclosure, while the widest variation in Risk coding was found in the 
level of School disclosure. It is important to note that both of these categories had a high 
percentage of missing data. Participants reported more comfort discussing their CF with others 
than performing CF treatments in front of others. 
Correlation matrices were calculated between all subscales and pertinent study variables. 
These are presented below in Tables 7 through 9. Correlations between subscales are shown first 
(Table 7), followed by correlations between subscales and demographic variables (Table 8), and 
ending with correlations between subscales and study variables (Table 9). As expected, subscales 
with the same coding scheme show high correlation with each other, for example, Count People 
subscale with Count Group subscale. Subscales also show correlation across coding techniques, 
for example, Count People subscale with Risk People subscale. Correlations between subscales 
and demographic and study variables will be discussed in-depth in Aim 3. 
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Table 7. 
 
Correlations between Subscale Grouping Methods 
1. All Count Subscales 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 
1. C-Friends ---              
2. C-Romantic Partner .443*** ---             
3. C-Work .717*** .328* ---            
4. C-School .654*** .402 .565* ---           
5. C-People .275** -.081 .415*** .140 ---          
6. C-Discussion .822*** .611*** .811*** .810*** .257** ---         
7. C-Treatments .798*** .466*** .815*** .830*** .362*** .682*** ---        
8. C-Close Friends .926*** .386*** .653*** .503** .230* .714*** .719*** ---       
9. C-Casual Friends .945*** .430*** .680*** .672*** .265** .805*** .774*** .746*** ---      
10. C-Boss .664*** .355* .968*** .575 .360** .787*** .765*** .655*** .576*** ---     
11. C-Coworkers .769*** .304* .969*** .656* .471*** .803*** .856*** .675*** .762*** .859*** ---    
12. C-Teachers .417* .298 .361 .926*** .008 .640*** .698*** .315 .432* .777* .393 ---   
13. C-Classmates .748*** .566* .646* .916*** .438* .865*** .843*** .599** .736*** .057 .719** .608** ---  
14. C-Overall .810*** .420*** .834*** .741*** .052 .719*** .639*** .744*** .763*** .801*** .831*** .583** .737*** --- 
Note. *p < .05. **p < .01. ***p < .001.  
2. All Risk Subscales 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. R-Friends ---           
2. R-Romantic Partner .268* ---          
3. R-Work .647*** .264* ---         
4. R-School .581*** .400* .623*** ---        
5. R-Close Friends .848*** .202 .452*** .379* ---       
6. R-Casual Friends .896*** .277** .645*** .613*** .524*** ---      
7. R-Boss .526*** .216 .911*** .351 .388*** .492*** ---     
8. R-Coworkers .646*** .281* .903*** .731*** .431*** .669*** .634*** ---    
9. R-Teachers .543*** .402* .558** .955*** .392** .536*** .380 .613** ---   
10. R-Classmates .598*** .390 .650*** .939*** .334* .689*** .280 .816*** .792*** ---  
11. R-Overall .780*** .553*** .851*** .854*** .599*** .744*** .744*** .794*** .794*** .847*** --- 
Note. *p < .05. **p < .01. ***p < .001. 
 
 
 
 
 
 
 
 
Table 7 continues 
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Table 7 continued 
3. Count Group Subscale and Risk Group Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 
1. C-Friends ---          
2. C-Romantic Partner .443*** ---         
3. C-Work .717*** .328* ---        
4. C-School .654*** .402 .565* ---       
5. C-Overall .810*** .420*** .834*** .741*** ---      
6. R-Friends -.834*** -.271* -.637*** -.609*** -.680*** ---     
7. R-Romantic Partner -.167 -1.0*** -.073 -.417 .004 .268* ---    
8. R-Work -.567*** -.221 -.797*** -.351 -.617*** .647*** .264* ---   
9. R-School -.516*** -.350 -.545* -.753*** -.528*** .581*** .400* .623*** ---  
10. R-Overall -.660*** -.412*** -.685*** -.733*** -.503*** .780*** .553*** .851*** .854*** --- 
Note. *p < .05. **p < .01. ***p < .001. 
4. Count Group Subscales and Risk People Subscales 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 
1. C-Friends ---         
2. C-Work .717*** ---        
3. C-School .654*** .565* ---       
4. R-Close Friends -.723*** -.486*** -.268 ---      
5. R-Casual Friends -.723*** -.590*** -.686*** .524*** ---     
6. R-Boss -.459*** -.602*** .214 .388*** .492*** ---    
7. R-Coworkers -.569*** -.751*** -.519* .431*** .669*** .634*** ---   
8. R-Teachers -.427** -.490* -.665*** .392** .536*** .380 .613** ---  
9. R-Classmates -.546*** -.541* -.710*** .334* .689*** .280 .816*** .792*** --- 
Note. *p < .05. **p < .01. ***p < .001. 
 
 
 
 
Table 7 continues 
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Table 7 continued 
5. Count Type Subscale and Risk Group Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 
1. C-People ---         
2. C-Discussion .257** ---        
3. C-Treatments .362*** .682*** ---       
4. C-Overall .052 .719*** .639*** ---      
5. R-Friends -.383*** -.629*** -.595*** -.680*** ---     
6. R-Romantic Partner -.117 -.292** -.240* .004 .268* ---    
7. R-Work -.349** -.533*** -.456*** -.617*** .647*** .264* ---   
8. R-School -.212 -.482** -.442** -.528*** .581*** .400* .623*** ---  
9. R-Overall -.479*** -.640*** -.620*** -.503*** .780*** .553*** .851*** .854*** --- 
Note. *p < .05. **p < .01. ***p < .001. 
6. Count Type Subscale and Risk People Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 
1. C-People ---         
2. C-Discussion .257** ---        
3. C-Treatments .362*** .682*** ---       
4. R-Close Friends -.394*** -.576*** -.536*** ---      
5. R-Casual Friends -.310*** -.559*** -.550*** .524*** ---     
6. R-Boss -.322** -.418*** -.296** .388*** .492*** ---    
7. R-Coworkers -.285** -.542*** -.525*** .431*** .669*** .634*** ---   
8. R-Teachers -.226 -.411** -.330* .392** .536*** .380 .613** ---  
9. R-Classmates -.245 -.475** -.523*** .334* .689*** .280 .816*** .792*** --- 
Note. *p < .05. **p < .01. ***p < .001. 
7. Count People Subscale and Risk Group Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 
1. C-Close Friends ---         
2. C-Casual Friends .746*** ---        
3. C-Boss .655*** .576*** ---       
4. C-Coworkers .675*** .762*** .859*** ---      
5. C-Teachers .315 .432* .777* .393 ---     
6. C-Classmates .599** .736*** .057 .719** .608** ---    
7. R-Friends -.819*** -.866*** -.583*** -.717*** -.377* -.706*** ---   
8. R-Work -.534*** -.649*** -.816*** -.833*** -.348 -.308 .647*** ---  
9. R-School -.519*** -.582*** -.410 -.652** -.646*** -.735*** .581*** .623*** --- 
Note. *p < .05. **p < .01. ***p < .001. 
Table 7 continues 
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Table 7 continued 
8. Count People Subscale and Risk People Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 
1. C-Close Friends ---            
2. C-Casual Friends .746*** ---           
3. C-Boss .655*** .576*** ---          
4. C-Coworkers .675*** .762*** .859*** ---         
5. C-Teachers .315 .432* .777* .393 ---        
6. C-Classmates .599** .736*** .057 .719** .608** ---       
7. R-Close Friends -.847*** -.513*** -.486*** -.485*** -.072 -.371 ---      
8. R-Casual Friends -.623*** -.954*** -.487*** -.725*** -.477* -.786*** .524*** ---     
9. R-Boss -.466*** -.494*** -.916*** -.503*** .159 .185 .388*** .492*** ---    
10. R-Coworkers -.520*** -.676*** -.661*** -.952*** -.463 -.551 .431*** .669*** .634*** ---   
11. R-Teachers -.464** -.455** -.452 -.530* -.624** -.554** .392** .536*** .380 .613** ---  
12. R-Classmates -.504** -.652*** -.245 -.750** -.556** -.843*** .334* .689*** .280 .816*** .792*** --- 
Note. *p < .05. **p < .01. ***p < .001. 
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Table 8. 
 
Correlations between Subscales and Demographic Variables 
1. Count Group Subscale 
  1. 2. 3. 4. 5. 6. 7. 8. 9. 
1. Friends ---         
2. Romantic Partner .443*** ---        
3. Work .717*** .328* ---       
4. School .654*** .402 .565* ---      
5. Overall .810*** .420*** .834*** .741*** ---     
6. Age -.220* .196 -.062 -.160 -.256** ---    
7. SES .028 .194 .040 -.037 -.040 .087 ---   
8. FEV1 % predicted -.039 .033 -.121 -.038 -.029 -.189* .053 ---  
9. BMI -.057 .189 -.036 -.114 -.058 .499** .130 .277** --- 
Note. *p < .05. **p < .01. ***p < .001. 
2. Count Type Subscale 
 1. 2. 3. 4. 5. 6. 7. 
1. People ---       
2. Discussion .257** ---      
3. Treatments .362*** .682*** ---     
4. Age .043 -.019 -.110 ---    
5. SES .063 -.001 .116 .087 ---   
6. FEV1 % predicted -.142 -.044 .015 -.189* .053 ---  
7. BMI -.091 -.005 -.004 .499** .130 .277** --- 
Note. *p < .05. **p < .01. ***p < .001.  
 
 
 
 
Table 8 continues 
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Table 8 continued 
3. Count People Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 
1. Close Friends ---          
2. Casual Friends .746*** ---         
3. Boss .655*** .576*** ---        
4. Coworkers .675*** .762*** .859*** ---       
5. Teachers .315 .432* .777* .393 ---      
6. Classmates .599** .736*** .057 .719** .608** ---     
7. Age -.232* -.192* -.038 -.115 -.011 -.093 ---    
8. SES .010 .025 .165 -.123 -.047 -.018 .087 ---   
9. FEV1 % predicted -.073 .002 -.156 -.132 .004 -.095 -.189* .053 ---  
10. BMI -.083 -.009 -.020 -.036 .052 -.127 .499** .130 .277** --- 
Note. *p < .05. **p < .01. ***p < .001.  
4. Risk Group Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 
1. Friends ---         
2. Romantic Partner .268* ---        
3. Work .647*** .264* ---       
4. School .581*** .400* .623*** ---      
5. Overall .780*** .553*** .851*** .854*** ---     
6. Age .147 -.149 -.136 .373* -.101 ---    
7. SES .006 .101 .107 .021 -.026 .087 ---   
8. FEV1 % predicted .096 .145 .250* .153 .208* -.189* .053 ---  
9. BMI .068 -.017 -.006 .344* .021 .499** .130 .277** --- 
Note. *p < .05. **p < .01. ***p < .001.  
 
 
 
 
Table 8 continues 
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Table 8 continued 
5. Risk People Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 
1. Close Friends ---          
2. Casual Friends .524*** ---         
3. Boss .388*** .492*** ---        
4. Coworkers .431*** .669*** .634*** ---       
5. Teachers .392** .536*** .380 .613** ---      
6. Classmates .334* .689*** .280 .816*** .792*** ---     
7. Age .125 .129 -.199 -.048 .385** .318* ---    
8. SES -.003 .019 -.022 .165 .007 .089 .087 ---   
9. FEV1 % predicted .065 .106 .268* .223* .137 .216 -.189* .053 ---  
10. BMI .054 .038 -.009 -.012 .334* .363* .499** .130 .277** --- 
Note. *p < .05. **p < .01. ***p < .001.  
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Table 9. 
 
Correlations between Subscales and Study Variables  
1. Count Group Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 
1. Friends ---              
2. Romantic Partner .443*** ---             
3. Work .717*** .328* ---            
4. School .654*** .402 .565* ---           
5. Overall .810*** .420*** .834*** .741*** ---          
6. MOS-SS .232*** .338** .250* .150 .169 ---         
7. Emotional .197* .106 .156 .090 .166 .331** ---        
8. Social .263** .099 .163 -.061 .207* .303** .529*** ---       
9. Respiratory .101 .127 -.043 -.069 .191* .044 .326*** .374*** ---      
10. Digestive .113 -.049 .073 .189 .183* -.034 .230** .035 .262** ---     
11. Self-efficacy .315*** .236* .208 .292 .259** .297** .287** .164 .165 .289** ---    
12. CES-D -.169 -.146 -.066 -.132 -.117 -.326*** -.772*** -.463*** -.294** -.207* -.308*** ---   
13. CMPR .028 .068 -.044 .113 .000 .153 .197* .075 .174* .212* .508*** -.219* ---  
14. CFKQ -.087 .260* -.074 -.215 -.110 .257** .043 -.078 -.006 -.001 .246** -.052 .158 --- 
Note. *p < .05. **p < .01. ***p < .001. 
2. Count Type Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 
1. People ---            
2. Discussion .257** ---           
3. Treatments .362*** .682*** ---          
4. MOS-SS .188* .257** .311*** ---         
5. Emotional -.024 .152 .102 .331*** ---        
6. Social .050 .184* .181* .303** .529*** ---       
7. Respiratory -.144 .050 -.059 .044 .326*** .374*** ---      
8. Digestive .061 .081 .004 -.034 .230** .035 .262** ---     
9. Self-efficacy .059 .160 .273** .297** .287** .164 .165 .289** ---    
10. CES-D -.002 -.177* -.075 -.326*** -.772*** -.463*** -.294** -.207* -.308*** ---   
11. CMPR .033 -.054 .030 .153 .197* .075 .174* .212* .508*** -.219* ---  
12. CFKQ -.026 -.067 -.074 .257** .043 -.078 -.006 -.001 .246** -.052 .158 --- 
Note. *p < .05. **p < .01. ***p < .001. 
 
Table 9 continues 
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Table 9 continued 
3. Count People Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 
1. Close Friends ---               
2. Casual Friends .746*** ---              
3. Boss .655*** .576*** ---             
4. Coworkers .675*** .762*** .859*** ---            
5. Teachers .315 .432* .777* .393 ---           
6. Classmates .599** .736*** .057 .719** .608** ---          
7. MOS-SS .253** .141 .274* .161 .220 .038 ---         
8. Emotional .179* .117 .139 .037 .161 -.047 .331*** ---        
9. Social .233* .208* .191 .087 .075 -.080 .303** .529*** ---       
10. Respiratory .041 .102 -.044 -.056 -.130 -.063 .044 .326*** .374*** ---      
11. Digestive .086 .033 -.020 .159 .071 .321 -.034 .230** .035 .262** ---     
12. Self-efficacy .313*** .304** .177 .197 .355 .255 .297** .287*** .164 .165 .289** ---    
13. CES-D -.140 -.100 -.051 .010 -.205 -.057 -.326*** -.772*** -.463*** -.294** -.207* -.308*** ---   
14. CMPR .056 -.030 .007 -.088 .186 .101 .153 .197* .075 .174* .212* .508*** -.219* ---  
15. CFKQ -.079 -.103 -.074 -.208 -.121 -.062 .257** .043 -.078 -.006 -.001 .246** -.052 .158 --- 
Note. *p < .05. **p < .01. ***p < .001. 
4. Risk Group Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 
1. Friends ---              
2. Romantic Partner .268* ---             
3. Work .647*** .264* ---            
4. School .581*** .400* .623*** ---           
5. Overall .780*** .553*** .851*** .854*** ---          
6. MOS-SS -.134 -.086 -.102 -.224 -.241** ---         
7. Emotional -.068 .055 -.026 -.157 .003 .331*** ---        
8. Social -.123 .115 -.007 .062 .000 .303*** .529*** ---       
9. Respiratory -.079 .164 .053 .042 .101 .044 .326*** .374*** ---      
10. Digestive -.112 -.058 -.014 -.083 -.004 -.034 .230** .035 .262** ---     
11. Self-efficacy -247** -.137 -.256* -.422** -.249** .297** .287** .164 .165 .289** ---    
12. CES-D .044 -.056 -.023 .200 .025 -.326*** -.772*** -.463*** -.294** -207* -.308*** ---   
13. CMPR -.086 -.077 .110 -.386** -.027 .153 .197* .075 .174* .212* .508*** -.219* ---  
14. CFKQ .049 -.174 -.114 -.088 -.091 .257** .043 -.078 -.006 -.001 .246** -.052 .158 --- 
Note. *p < .05. **p < .01. ***p < .001. 
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Table 9 continued 
5. Risk People Subscale 
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 
1. Close Friends ---               
2. Casual Friends .524*** ---              
3. Boss .388*** .492*** ---             
4. Coworkers .431*** .669*** .634*** ---            
5. Teachers .392** .536*** .380 .613** ---           
6. Classmates .334* .689*** .280 .816*** .792*** ---          
7. MOS-SS -.199* -.061 -.087 -.070 -.241 -.126 ---         
8. Emotional -.091 -.049 -.017 -.041 -.180 -.103 .331*** ---        
9. Social -.112 -.099 -.024 .009 .086 .071 .303** .529*** ---       
10. Respiratory -.025 -.086 .021 .078 -.039 .098 .044 .326*** .374*** ---      
11. Digestive -.087 -.077 .039 -.103 -.119 -.080 -.034 .230** .035 .262** ---     
12. Self-efficacy -.207* -.237** -.181 -.259* -.331* -.439** .297** .287** .164 .165 .289** ---    
13. CES-D .073 .025 -.027 -.025 .196 .153 -.326*** -.772*** -.463*** -.294** -.207* -.308*** ---   
14. CMPR -.114 -.052 .188 .047 -.338* -.374* .153 .197* .075 .174* .212* .508*** -.219* ---  
15. CFKQ .030 .053 -.140 -.032 -.034 -.157 .257** .043 -.078 -.006 -.001 .246** -.052 .158 --- 
Note. *p < .05. **p < .01. ***p < .001. 
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Aim 2 
Aim 2a. It was hypothesized that female participants would score higher than male 
participants on all subscales of each subscale grouping method. Female participants scored 
higher on the Count and Risk Friends subscale (t(121) = -2.23, p = .03; t(124) = 3.12, p = .002), 
the People Told subscale t(123) = -2.66, p = .009), the Count and Risk Close Friends subscale 
(t(119) = -2.26, p = .03; t(122.6) = 2.28, p = .02), the Risk Casual Friends subscale t(123) = 2.79, 
p = .006), and the Risk Overall score t(124) = 2.39, p = .02). No other subscales were 
significantly different between genders. Findings are presented below in Tables 10, 11, and 12. 
Table 10. 
 
T-test Analyses Assessing for Differences in Group Subscales by Gender 
1. Friends 
 Count Risk 
 Mean (SD) t df p Mean (SD) t df p 
Male (n=63) 6.24 (2.55) -2.23 121 .03* 9.97 (5.80) 3.12 124 .002** 
Female (n=60) 7.23 (2.38)    6.98 (4.91)    
2. Romantic Partner 
 Count Risk 
 Mean (SD) t df p Mean (SD) t df p 
Male (n=41) 9.37 (1.56) -.082 86 .94 1.90 (3.16) -.654 87 .52 
Female (n=47) 9.39 (1.61)    2.43 (4.22)    
3. Work 
 Count Risk 
 Mean (SD) t df p Mean (SD) t df p 
Male (n=43) 5.86 (2.97) -.582 77 .56 11.79 (6.94) 1.21 94 .23 
Female (n=36) 6.25 (3.05)    10.02 (7.31)    
4. School 
 Count Risk 
 Mean (SD) t df p Mean (SD) t df p 
Male (n=12) 5.04 (2.73) -1.42 27 .17 16.36 (6.45) 1.62 43 .11 
Female (n=17) 6.35 (2.24)    12.92 (7.43)    
Note. *p < .05. **p < .01. ***p < .001. 
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Table 11. 
 
T-test Analyses Assessing for Differences in Type Subscales by Gender 
1. People Told 
 Count 
 Mean (SD) t df p 
Male (n=65) 1.55 (.31) -2.66 123 .009** 
Female (n=60) 1.69 (.25)    
2. Comfort in Discussion 
 Count 
 Mean (SD) t df p 
Male (n=65) 7.25 (2.28) -1.74 123 .084 
Female (n=60) 7.93 (2.06)    
3. Comfort in Treatments 
 Count 
 Mean (SD) t df p 
Male (n=64) 5.86 (2.63) -1.39 122 .168 
Female (n=60) 6.48 (2.35)    
Note. *p < .05. **p < .01. 
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Table 12. 
 
T-test Analyses Assessing for Differences in People Subscales by Gender 
1. Close Friends 
 Count Risk 
 Mean (SD) t df p Mean (SD) t df p 
Male (n=62) 7.18 (2.52) -2.26 119 .03* 6.50 (5.95) 2.28 122.6 .02* 
Female (n=59) 8.18 (2.34)    4.23 (5.18)    
2. Casual Friends 
 Count Risk 
 Mean (SD) t df p Mean (SD) t df p 
Male (n=54) 5.29 (2.94) -1.45 106 .15 13.23 (6.76) 2.79 123 .006** 
Female (n=54) 6.09 (2.76)    9.87 (6.62)    
3. Boss 
 Count Risk 
 Mean (SD) t df p Mean (SD) t df p 
Male (n=35) 6.16 (3.02) -.598 66 .55 10.15 (8.12) 1.17 91 .25 
Female (n=33) 6.61 (3.17)    8.21 (7.71)    
4. Coworkers 
 Count Risk 
 Mean (SD) t df p Mean (SD) t df p 
Male (n=39) 5.51 (3.10) -.950 70 .35 13.06 (7.40) .79 93 .43 
Female (n=33) 6.19 (2.98)    11.82 (7.85)    
5. Teachers 
 Count Risk 
 Mean (SD) t df p Mean (SD) t df p 
Male (n=10) 5.50 (2.71) -1.103 25 .28 15.34 (7.29) 1.85 42 .07 
Female (n=17) 6.65 (2.55)    10.90 (8.34)    
6. Classmates 
 Count Risk 
 Mean (SD) t df p Mean (SD) t df p 
Male (n=8) 5.94 (2.79) .056 22 .96 17.37 (6.45) 1.46 42 .15 
Female (n=16) 5.88 (2.47)    14.30 (7.25)    
7. Overall 
 Count Risk 
 Mean (SD) t df p Mean (SD) t df p 
Male (n=63) 4.53 (2.45) -.772 121 .44 9.08 (4.73) 2.39 124 .02* 
Female (n=60) 4.84 (2.12)    7.03 (4.89)    
Note. *p < .05. **p < .01.  
 
Aim 2b. It was hypothesized that participants with more severe CF would score higher 
on all subscales of each subscale grouping method. Participants with more severe CF scored 
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higher on the Risk Work subscale (F(2, 94) = 3.61, p = .03), the Risk Boss subscale (F(2, 91) = 
3.68, p = .03), and the Risk Overall score (F(2, 120) = 3.76, p = .03), indicating that these 
participants disclosed more at work, to their boss, and overall, than participants with less severe 
CF. No other subscales were significantly different between illness severity groups. ANOVA 
findings as well as means and standard deviations are presented below in Tables 13-18. 
Table 13. 
 
ANOVA Assessing for Differences in Group Subscales by Illness Severity 
1. Friends 
 Count Risk 
Source df SS MS F p df SS MS F p 
Between groups 2 11.25 5.62 .877 .42 2 86.65 43.33 1.35 .26 
Within groups 115 737.09 6.41   118 3798.44 32.19   
Total 117 748.34    120 3885.09    
2. Romantic Partner 
 Count Risk 
Source df SS MS F p df SS MS F p 
Between groups 2 6.49 3.24 1.67 .19 2 51.99 25.99 1.89 .16 
Within groups 82 159.44 1.94   83 1144.32 13.79   
Total 84 165.92    85 1196.31    
3. Work 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 31.08 15.54 1.77 .18 2 342.82 171.41 3.61 .03* 
Within groups 76 668.39 8.79   92 4373.79 47.54   
Total 78 699.47    94 4716.61    
4. School 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 8.75 4.38 .69 .51 2 199.16 99.58 2.08 .14 
Within groups 27 169.00 6.26   42 2014.29 47.96   
Total 29 177.75    44 2213.45    
5. Overall 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 4.44 2.22 .42 .66 2 174.62 87.31 3.76 .03* 
Within groups 115 615.09 5.35   118 2739.09 23.21   
Total 117 619.54    120 2913.72    
Note. *p < .05. 
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Table 14. 
 
ANOVA Descriptives of Group Subscales by Illness Severity 
1. Friends 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
Mild 61 6.56 2.72 .42 62 9.04 5.92 .26 
Moderate 48 6.59 2.33  50 8.81 5.47  
Severe 15 7.57 2.28  15 6.32 4.62  
2. Romantic Partner 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
Mild 41 9.48 1.07 .19 43 2.89 5.12 .16 
Moderate 36 9.0 2.17  35 1.77 1.71  
Severe 12 10.0 0  12 1.0 0  
3. Work 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
Mild 38 5.74 3.14 .18 49 12.21 7.39 .03* 
Moderate 30 5.83 2.94  35 10.97 6.55  
Severe 11 7.59 2.30  12 6.27 6.03  
4. School 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
Mild 18 5.42 2.59 .51 27 14.36 6.78 .14 
Moderate 10 6.0 2.36  17 15.52 7.24  
Severe 2 7.5 2.12  2 4.63 3.71  
5. Overall 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
Mild 61 4.65 2.49 .66 62 8.86 4.97 .03* 
Moderate 48 4.51 2.16  50 8.17 4.65  
Severe 15 5.21 1.88  15 5.04 4.39  
Note. *p < .05. **p < .01.  
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Table 15. 
 
ANOVA Assessing for Differences in Type Subscales by Illness Severity 
1. People Told 
 Count 
 df SS MS F p 
Between groups 2 .45 .226 2.79 .07 
Within groups 117 9.48 .081   
Total 119 9.93    
2. Comfort in Discussion 
 Count 
 df SS MS F p 
Between groups 2 21.39 10.69 2.33 .10 
Within groups 117 536.57 4.59   
Total 119 557.96    
3. Comfort in Treatment 
 Count 
 df SS MS F p 
Between groups 2 4.91 2.45 .38 .69 
Within groups 117 749.86 6.46   
Total 119 754.76    
 
Table 16. 
 
ANOVA Descriptives of Type Subscales by Illness Severity 
1. People Told     
 Count 
 Group N Mean SD p 
Mild 61 1.58 2.35 .07 
Moderate 50 1.61 0.35  
Severe 15 1.77 0.25  
2. Comfort in Discussion 
    
 Count 
 Group N Mean SD p 
Mild 61 7.44 2.07 .10 
Moderate 50 7.34 2.36  
Severe 15 8.74 1.89  
3. Comfort in Treatment 
    
 Count 
 Group N Mean SD p 
Mild 61 6.13 2.59 .69 
Moderate 46 5.99 2.29  
Severe 15 6.67 2.89  
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Table 17. 
ANOVA Assessing for Differences in People Subscales by Illness Severity 
1. Close Friends 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 6.59 3.29 .54 .59 2 78.23 39.11 1.16 .32 
Within groups 113 696.03 6.16   117 3930.47 33.59   
Total 115 702.63    119 4008.698    
2. Casual Friends 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 12.41 6.20 .75 .48 2 98.40 49.20 1.01 .37 
Within groups 100 827.43 8.27   117 5676.83 48.52   
Total 102 839.84    119 5775.23    
3. Boss 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 40.53 20.27 2.22 .12 2 433.89 216.95 3.68 .03* 
Within groups 65 594.66 9.15   89 5243.87 58.92   
Total 67 635.19    91 5677.77    
4. Coworkers 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 21.80 10.90 1.18 .31 2 264.58 132.29 2.37 .09 
Within groups 69 635.28 9.21   91 5074.07 55.76   
Total 71 657.08    93 5338.65    
5. Teachers 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 4.43 2.21 .32 .73 2 185.04 92.52 1.47 .24 
Within groups 25 174.74 6.99   41 2568.09 63.08   
Total 27 179.17    43 2771.14    
6. Classmates 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 9.51 4.75 .71 .50 2 214.91 107.46 2.36 .11 
Within groups 22 148.05 6.73   41 1870.79 45.63   
Total 24 157.56    43 2085.69    
Note. *p < .05. 
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Table 18. 
 
ANOVA Descriptives of People Subscales by Illness Severity 
1. Close Friends 
 Count Risk 
 n Mean SD p Group N Mean SD p 
Mild 61 7.41 2.74 .59 62 5.82 5.99 .32 
Moderate 46 7.73 2.34  49 5.75 6.12  
Severe 15 8.17 2.01  15 3.37 2.30  
2. Casual Friends 
 Count Risk 
 n Mean SD p Group N Mean SD p 
Mild 52 5.67 2.99 .48 62 12.26 7.10 .37 
Moderate 43 5.42 2.69  49 11.79 6.39  
Severe 13 6.69 2.87  15 9.27 7.57  
3. Boss 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
Mild 30 6.23 3.19 .12 47 10.90 8.41 .03* 
Moderate 27 5.85 3.11  34 8.74 7.39  
Severe 11 8.09 2.18  12 4.42 5.62  
4. Coworkers 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
Mild 35 5.49 3.23 .31 48 13.35 7.61 .09 
Moderate 26 5.75 2.80  35 12.86 7.31  
Severe 11 7.09 2.89  12 8.13 7.42  
5. Teachers 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
Mild 17 5.91 2.82 .73 27 12.48 8.08 .24 
Moderate 9 6.5 2.28  16 14.41 7.87  
Severe 2 7.25 2.48  2 3.75 2.48  
6. Classmates 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
Mild 14 5.43 2.65 .50 27 16.24 6.59 .11 
Moderate 9 5.83 2.59  16 15.94 7.04  
Severe  2 7.75 1.77  2 15.66 6.93  
Note. *p < .05. **p < .01.  
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Aim 2c. It was hypothesized that participants with more complex CF regimens would 
score higher on all subscales of each subscale grouping method. Higher scores on subscales 
indicate greater levels of disclosure. No subscales were significantly different between regimen 
complexity groups. Nonsignificant results may be due to the partial scoring technique used. 
ANOVA findings and descriptives are presented below in Tables 19-24. 
Table 19. 
 
ANOVA Assessing for Differences in Group Subscales by Regimen Complexity 
1. Friends 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 1.07 .535 .08 .92 2 12.98 6.49 .198 .82 
Within groups 115 747.27 6.49   118 3872.12 32.82   
Total 117 748.34    120 3885.09    
2. Romantic Partner 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 3.26 1.63 .82 .44 2 22.56 11.28 .798 .45 
Within groups 82 162.67 1.98   83 1173.74 14.14   
Total 84 165.92    85 1196.31    
3. Work 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 25.61 12.80 1.44 .24 2 74.21 37.11 .735 .48 
Within groups 76 673.86 8.87   92 4642.40 50.46   
Total 78 699.47    94 4716.61    
4. School 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 20.84 10.42 1.79 .19 2 46.54 23.27 .451 .64 
Within groups 27 156.92 5.81   42 2166.91 51.59   
Total 29 177.75    44 2213.45    
5. Overall 
          
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 1.19 .59 .11 .89 2 4.09 2.05 .083 .92 
Within groups 115 618.35 5.38   118 2609.63 24.66   
Total 117 619.54    120 2913.72    
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Table 20. 
 
ANOVA Descriptives of Group Subscales by Regimen Complexity 
1. Friends 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
RC-1 10 7.08 2.54 .92 10 7.48 5.76 .82 
RC-2 94 6.64 2.55  97 8.75 5.71  
RC-3 20 6.75 2.53  20 8.64 5.39  
2. Romantic Partner 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
RC-1 8 9.38 1.06 .44 8 1.63 13.63 .45 
RC-2 66 9.23 1.78  67 2.52 4.28  
RC-3 15 9.87 0.52  15 1.13 0.52  
3. Work 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
RC-1 4 8.5 1.78 .24 8 13.63 8.33 .48 
RC-2 62 5.90 2.99  74 10.95 7.06  
RC-3 13 5.90 3.17  14 9.89 6.93  
4. School 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
RC-1 3 3.83 0.76 .19 4 14.56 5.02 .64 
RC-2 19 6.33 2.47  34 14.89 7.34  
RC-3 8 5.09 2.57  8 12.03 7.11  
5. Overall 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
RC-1 10 4.78 2.06 .89 10 8.5 5.47 .92 
RC-2 94 4.68 2.43  97 8.19 4.94  
RC-3 20 4.49 1.69  20 7.70 4.60  
Note. RC-1=least complex regimen; RC-2=moderately complex regimen; RC-3=most complex regimen.  
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Table 21. 
 
ANOVA Assessing for Differences in Type Subscales by Regimen Complexity 
1. People Told 
 df SS MS F p 
Between groups 2 .022 .011 .13 .88 
Within groups 117 9.91 .085   
Total 119 9.93    
2. Comfort in Discussion 
 df SS MS F p 
Between groups 2 6.78 3.39 .72 .49 
Within groups 117 551.18 4.71   
Total 119 557.96    
3. Comfort in Treatment 
 df SS MS F p 
Between groups 2 6.93 3.46 .54 .59 
Within groups 116 747.83 6.45   
Total 118 754.76    
 
Table 22. 
 
ANOVA Descriptives of Type Subscales by Regimen Complexity 
  
1. People Told     
 Count 
 Group N Mean SD p 
RC-1 10 1.62 0.29 .88 
RC-2 94 1.61 0.29  
RC-3 20 1.62 0.29  
2. Comfort in Discussion 
    
 Count 
 Group N Mean SD p 
RC-1 10 7.89 1.72 .49 
RC-2 95 7.62 2.19  
RC-3 21 7.08 2.44  
3. Comfort in Treatment 
    
 Count 
 Group N Mean SD p 
RC-1 10 6.94 1.99 .59 
RC-2 95 6.08 2.57  
RC-3 20 6.06 2.45  
Note. RC-1= least complex regimen; RC-2=moderately complex regimen; RC-3=most complex regimen.  
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Table 23. 
 
ANOVA Assessing for Differences in People Subscales by Regimen Complexity 
1. Close Friends 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 4.82 2.41 .39 .68 2 23.93 11.96 .351 .71 
Within groups 113 697.81 6.18   117 3984.77 34.06   
Total 115 702.63    119 4008.69    
2. Casual Friends 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 2.92 1.46 .18 .84 2 4.81 2.41 .049 .95 
Within groups 100 836.91 8.37   117 5770.42 49.32   
Total 102 839.84    119 5775.23    
3. Boss 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 37.56 18.78 204 .14 2 41.40 20.70 .327 .72 
Within groups 65 597.63 9.19   89 5636.37 63.33   
Total 67 635.19    91 5677.77    
4. Coworkers 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 12.24 6.12 .66 .52 2 50.42 25.21 .434 .65 
Within groups 69 644.84 9.35   91 5288.24 58.11   
Total 71 657.08    93 5338.65    
5. Teachers 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 23.48 11.74 1.89 .17 2 38.98 19.49 .292 .75 
Within groups 25 155.69 6.23   41 2732.16 66.64   
Total 27 179.17    43 2771.14    
7. Classmates 
 Count Risk 
 df SS MS F p df SS MS F p 
Between groups 2 33.19 16.59 2.94 .07 2 49.96 24.98 .503 .61 
Within groups 22 124.37 5.65   41 2035.74 49.65   
Total 24 157.56    43 2085.69    
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Table 24. 
 
ANOVA Descriptives of People Subscales by Regimen Complexity 
1. Close Friends 
 Count Risk 
 n Mean SD p Group N Mean SD p 
RC-1 10 8.1 2.44 .68 10 4.0 4.86 .71 
RC-2 92 7.46 2.51  96 5.69 5.79  
RC-3 20 8.12 2.53  20 5.35 6.15  
2. Casual Friends 
 Count Risk 
 n Mean SD p Group N Mean SD p 
RC-1 8 6.19 3.10 .84 10 10.95 7.83 .95 
RC-2 82 5.74 2.82  96 11.76 6.81  
RC-3 18 5.28 3.08  20 11.93 7.20  
3. Boss 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
RC-1 4 9.0 2.0 .14 7 10.14 10.25 .72 
RC-2 53 6.05 3.11  72 9.51 7.85  
RC-3 11 7.0 2.88  14 7.64 7.67  
4. Coworkers 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
RC-1 3 7.33 2.52 .66 7 15.0 8.14 .65 
RC-2 57 5.89 3.05  74 12.35 7.56  
RC-3 12 5.17 3.16  14 12.14 7.81  
5. Teachers 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
RC-1 3 3.67 1.61 .17 4 12.13 6.06 .75 
RC-2 19 6.34 2.56  33 13.36 8.35  
RC-3 6 7..0 2.55  8 10.69 8.03  
6. Classmates 
 Count Risk 
 Group N Mean SD p Group N Mean SD p 
RC-1 2 4.5 2.83 .07 4 17.0 5.66 .61 
RC-2 15 6.7 2.24  33 16.05 7.13  
RC-3 8 4.31 2.56  8 13.38 6.97  
Note. RC-1= least complex regimen; RC-2= moderately complex regimen; RC-3= most complex regimen. 
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Aim 3 
 Correlations using Pearson’s r were conducted to determine convergent and discriminant 
validity properties of the CFDS. Analyses were conducted including all possible participants 
from the total sample. Correlations between subscales and non-hypothesized variables (i.e., age 
and body mass index [BMI]) will be discussed at the end of this section. 
 Aim 3a. It was hypothesized that the Friends and Romantic Partner subscales, and 
Overall Disclosure Score, would be significantly positively associated with the MOS-SS. The 
MOS-SS is a self-report measure of social support. In the overall sample, there were positive 
correlations between the Friends (r = .23, p = .01) and Romantic Partner (r = .34, p < .001) 
subscales, and the MOS-SS. In each instance, higher levels of disclosure were associated with 
greater social support. 
 Aim 3b. It was hypothesized that all Count Group subscales and the Overall Disclosure 
score would be significantly positively associated with the Emotional and Social Functioning 
subscales of the CFQ-R. In the overall sample, the Friends subscale was positively associated 
with the Emotional Functioning (r = .20, p = .028) and Social Functioning (r = .26, p = .003) 
subscales. The Overall Disclosure score was positively associated with the Social Functioning 
subscale (r = .21, p = .021). These results reflect more frequent disclosure with better emotional 
and/or social functioning. 
 Aim 3c. It was hypothesized that all Count Group subscales and the Overall Disclosure 
score would be significantly positively associated with the Respiratory and Digestive Symptoms 
subscales of the CFQ-R. In the overall sample, the Overall Disclosure score was positively 
associated with the Respiratory Symptoms (r = .19, p = .034) and Digestive Symptoms subscales 
(r = .18, p = .041). 
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 Aim 3d. It was hypothesized that all Count Group subscales and the Overall Disclosure 
score would be significantly negatively associated with the CES-D. No significant associations 
were found in the overall sample. 
 Aim 3e. It was hypothesized that all Count Group subscales and the Overall Disclosure 
score would be significantly positively associated with the CMPR. There were no significant 
associations between disclosure and CMPR in the overall sample. 
 Aim 3f. It was hypothesized that all Count Group subscales and the Overall Disclosure 
score would not significantly correlate with the CFKQ. The Romantic Partner subscale was 
positively related to the CFKQ (r = .26, p = .014) in the overall sample. 
 Aim 3g. It was hypothesized that all Count Group subscales and the Overall Disclosure 
score would not significantly correlate with participants’ insurance status. No significant 
associations were identified in the overall sample. 
 Aim 3h. It was hypothesized that the People Told and Comfort in Discussion subscales, 
and Overall Disclosure score, would be significantly positively associated with the MOS-SS. In 
the overall sample, the People Told (r = .19, p = .035) and Comfort in Discussion (r = .26, p = 
.004) subscales were positively related to the MOS-SS. 
 Aim 3i. It was hypothesized that the Comfort in Treatments subscale would be 
significantly positively associated with the Self-Efficacy Questionnaire. A positive correlation 
was found between the Comfort in Treatments subscale and the Self-Efficacy Questionnaire (r = 
.27, p = .002) in the overall sample. 
 Aim 3j. It was hypothesized that all Type of Disclosure subscales and the Overall 
Disclosure score would be significantly positively associated with the Emotional and Social 
Functioning subscales of the CFQ-R. In the overall sample, the Comfort in Discussion (r = .18, p 
= .039) and Comfort in Treatments (r = .18, p = .044) subscales, and the Overall Disclosure 
score (r = .21, p = .021), were positively related with the Social Functioning Subscale. 
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 Aim 3k. It was hypothesized that the People Told subscale would be significantly 
positively associated with the Respiratory and Digestive Symptoms subscales of the CFQ-R. No 
significant associations were found in the overall sample. 
 Aim 3l. It was hypothesized that all Type of Disclosure subscales and the Overall 
Disclosure score would be significantly negatively associated with the CES-D. A negative 
correlation was found between the Comfort in Discussion subscale and the CES-D (r = -.18, p = 
.047) in the overall sample. 
Aim 3m. It was hypothesized that all Type of Disclosure subscales and the Overall 
Disclosure score would be significantly positively associated with the CMPR. No significant 
associations were found in the overall sample. 
 Aim 3n. It was hypothesized that all Type of Disclosure subscales and the Overall 
Disclosure score would not significantly correlate with the CFKQ. No significant associations 
were found in the overall sample. 
 Aim 3o. It was hypothesized that all Type of Disclosure subscales and the Overall 
Disclosure score would not significantly correlate with participants’ insurance status. No 
significant associations were found in the overall sample. 
Aim 3p. It was hypothesized that the Close Friends subscale, Romantic Partner subscale, 
and Overall Disclosure score, would be significantly positively associated with the MOS-SS. 
There were positive correlations between the Close Friends subscale (r = .25, p = .005) and the 
Romantic Partner subscale (r = .34, p < .001), and the MOS-SS in the overall sample. 
 Aim 3q. It was hypothesized that all Count People subscales and the Overall Disclosure 
score would be significantly positively associated with the Emotional and Social Functioning 
subscales of the CFQ-R. In the overall sample, the Close Friends subscale was positively 
associated with the Emotional Functioning (r = .18, p = .048) and Social Functioning (r = .23, p 
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= .010) subscales. The Casual Friends subscale (r = .21, p = .031) Overall Disclosure score (r = 
.21, p = .021) were positively associated with the Social Functioning subscale. 
 Aim 3r. It was hypothesized that all Count People subscales and the Overall Disclosure 
score would be significantly positively associated with the Respiratory and Digestive Symptoms 
subscales of the CFQ-R. Positive correlations were found between the Overall Disclosure score 
and the Respiratory Symptoms (r = .19, p = .034) and Digestive Symptoms (r = .18, p = .041) 
subscales in the overall sample. 
 Aim 3s. It was hypothesized that all Count People subscales and the Overall Disclosure 
score would be significantly negatively associated with the CES-D. No significant associations 
were found in the overall sample. 
 Aim 3t. It was hypothesized that all Count People subscales and the Overall Disclosure 
score would be significantly positively associated with the CMPR. No significant associations 
were found between disclosure and adherence in the overall sample. 
 Aim 3u. It was hypothesized that all Count People subscales and the Overall Disclosure 
score would not significantly correlated with the CFKQ. In the overall sample, the Romantic 
Partner subscale was positively related to the CFKQ (r = .26, p = .014). 
 Aim 3v. It was hypothesized that all Count People subscales and the Overall Disclosure 
score would not significantly correlate with participants’ insurance status. This hypothesis was 
supported- insurance status was not associated with any Count People subscale or the Overall 
Disclosure score in the overall sample. 
Aim 3w. It was hypothesized that the Risk Friends subscale, Risk Romantic Partner 
subscale, and Risk Overall Disclosure score would be significantly negatively associated with 
the MOS-SS. There was an inverse correlation between the Overall Disclosure score and the 
MOS-SS (r = -.24, p = .006) in the overall sample. 
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 Aim 3x. It was hypothesized that all Risk Group subscales and the Overall Disclosure 
score would be significantly negatively associated with the Emotional and Social Functioning 
subscales of the CFQ-R. No significant correlations were found in the overall sample. 
 Aim 3y. It was hypothesized that all Risk Group subscales and the Overall Disclosure 
score would be significantly negatively associated with the Respiratory and Digestive Symptoms 
subscales of the CFQ-R. No significant associations were found in the overall sample. 
 Aim 3z. It was hypothesized that all Risk Group subscales and the Overall Disclosure 
score would be significantly positively associated with the CES-D. No significant associations 
were found in the overall sample. 
 Aim 3aa. It was hypothesized that all Risk Group subscales and the Overall Disclosure 
score would be significantly negatively associated with the CMPR. The School subscale was 
negatively related to CMPR (r = -.39, p = .008) in the overall sample. 
 Aim 3ab. It was hypothesized that all Risk Group subscales and the Overall Disclosure 
score would not significantly correlate with the CFKQ. No significant associations were found in 
the overall sample. 
 Aim 3ac. It was hypothesized that all Risk Group subscales and the Overall Disclosure 
score would not significantly correlate with participants’ insurance status. This hypothesis was 
supported. 
Aim 3ad. It was hypothesized that the Close Friends subscale, Romantic Partner 
subscale, and Overall Disclosure score would be significantly negatively associated with the 
MOS-SS. In the overall sample, there was a negative correlation between the Close Friends 
subscale (r = -.20, p = .026) and Overall Disclosure score (r = -.24, p = .006), and the MOS-SS. 
 Aim 3ae. It was hypothesized that all Risk People subscales and the Overall Disclosure 
score would be significantly negatively associated with the Emotional and Social Functioning 
subscales of the CFQ-R. No significant correlations were found in the overall sample. 
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 Aim 3af. It was hypothesized that all Risk People subscales and the Overall Disclosure 
score would be significantly negatively associated with the Respiratory and Digestive Symptoms 
subscales of the CFQ-R. No significant associations were found in the overall sample. 
 Aim 3ag. It was hypothesized that all Risk People subscales and the Overall Disclosure 
score would be significantly positively associated with the CES-D. No significant associations 
were found in the overall sample. 
 Aim 3ah. It was hypothesized that all Risk People subscales and the Overall Disclosure 
score would be significantly negatively associated with CMPR. In the overall sample, the 
Teachers (r = -.34, p = .023) and Classmates (r = -.37, p = .011) subscales were negatively 
related to CMPR. 
 Aim 3ai. It was hypothesized that all Risk People subscales and the Overall Disclosure 
score would not significantly correlate with the CFKQ. No significant associations were found in 
the overall sample. 
 Aim 3aj. It was hypothesized that all Risk People subscales and the Overall Disclosure 
score would not significantly correlate with participants’ insurance status. In the overall sample, 
a negative correlation was found between the Boss subscale and insurance status (r = -.23, p = 
.030). 
 Non-hypothesized correlations. Non-hypothesized correlations between subscales and 
demographic variables were also found. These will be discussed below by subscale types. 
 Count Group subscales. The Friends subscale (r = -.22, p = .014) and Overall Disclosure 
score (r = -.26, p = .004) were significantly negatively associated with age, with younger 
participants disclosing more frequently to friends and overall. 
 Count Type subscales. No significant correlations with non-hypothesized variables were 
found in these subscales. 
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 Count People subscales. The Close Friends (r = -.23, p = .010) and Casual Friends (r = -
.19, p = .047) subscales, and the Overall Disclosure score (r = -.26, p = .004) were significantly 
negatively correlated with age, with younger participants disclosing more frequently to friends 
and overall. 
 Risk Group subscales. The School subscale was significantly positively associated with 
age (r = .37, p = .011), with older participants disclosing less frequently to classmates and 
teachers. The School subscale was also significantly positively associated with BMI (r = .34, p = 
.019), with higher levels of disclosure at school seen in participants with lower body mass 
indices. 
 Risk People subscales. The Teacher and Classmates subscales were significantly 
positively associated with age (r = .39, p = .009; r = .33, p = .025) and BMI (r = .32, p = .033; r 
= .36, p = .014). Lower levels of disclosure to teachers and classmates were seen in older 
participants and participants with lower body mass indices. 
Aim 4 
This aim was to determine the “best” method for grouping the CF Disclosure Scale. The 
best method was determined by normal distribution of responses, Eigenvalues above 1.0, scree 
plots with significant values for postulated subscales, higher internal consistency (α ≥ 0.7), and 
acceptable convergent and discriminant validity (based on effect sizes). Findings will be 
discussed in sections based on each criterion. 
Response distribution. One criterion against which grouping methods were measured 
was normal distribution of responses. Data were not distributed normally in any of the grouping 
methods. The graphs below (Figures 5-8) show frequency distributions organized by subscale 
grouping. Type of Disclosure subscales are not shown as their data could not be normally 
distributed. 
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Figure 4. Distribution of responses organized by Count coding and People subscale grouping. 
 
 
Figure 5. Distribution of responses organized by Count coding and Group subscale grouping. 
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Figure 6. Distribution of responses organized by Risk coding and People subscale grouping. 
 
 
Figure 7. Distribution of responses organized by Risk coding and Group subscale grouping. 
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determine their contribution to the questionnaire. Component values above 0.4 indicate a 
question should be retained (Field, 2009). Based on these values, it was determined that all 
questions should be retained. These values are displayed below in Table 25. 
 
Table 25. 
 
Component Values of CFDS Questions Obtained from Exploratory Factor Analysis 
Question Number Component Value 
1 -.503 
2 .698 
3 .727 
4 -.523 
5 .764 
6 .791 
7 .655 
8 .652 
9 .644 
10 .488 
11 .570 
12 .603 
13 .537 
14 .665 
15 .713 
16 -.653 
17 .541 
18 .616 
19 .524 
20 .630 
21 .682 
 
 
Multiple imputation was not an appropriate strategy by which to evaluate the factor 
structure of subscales because the missing data in this questionnaire were not traditional missing 
data (e.g., missing at random). There was a large number of missing data; only four participants 
(3.1%) answered every disclosure question. Approximately 30% (n = 37) of participants did not 
have a romantic partner at their baseline evaluation. Twenty-five percent of the sample (n = 32) 
was not currently working, and only 36% (n = 45) of participants were in school. Thirty-three 
percent of all disclosure data was missing. An attempt was made to evaluate the questions 
grouped into categories with only participants who answered them. Using this method, guesses 
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would not be made regarding theoretical disclosure patterns of participants in hypothetical 
situations (e.g., if they had a romantic partner, if they were in school, etc.). 
Smaller groups of subscales were used in attempted factor analyses, but, due to small Ns 
across categories, the only usable combination was Friends and Romantic Partner (n=75). Two 
factors were extracted from this analyses, with “friends” and “romantic partner” questions 
allocated to two separate subscales. Factor loadings are presented below in Table 26. 
 
Table 26. 
 
Factor Loadings of CFDS “Friend” and “Romantic Partner” Questions 
Question Factor 1 Factor 2 
Do your close friends know that you have CF? .456 -.441 
Comfort in discussing your CF experience with your 
close friends. 
.815 -.245 
Comfort in doing your CF treatments in front of 
your close friends. 
.836 -.203 
Do your casual friends know that you have CF? .574 -.199 
Comfort in discussing your CF experience with your 
casual friends. 
.884 -.069 
Comfort in doing your CF treatments in front of 
your casual friends. 
.809 -.176 
Does your current romantic partner know that you 
have CF? 
.121 .717 
Comfort in discussing your CF experience with your 
current romantic partner. 
.616 .656 
Comfort in doing your CF treatments in front of 
your current romantic partner. 
.602 .659 
 
 
Individual factor analyses were run for questions grouped into separate categories of 
“Friends" "Romantic Partner" "Work" and "School." The "does X know about your CF" question 
was not included in these analyses. No missing data were included. Results from the separate 
factor analyses indicate each question of the CFDS strongly loads onto one factor when placed 
into these groups. Eigenvalues for each group are below in Table 27. 
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Table 27. 
 
CFDS Subscale Eigenvalues  
Subscale Eigenvalues % variance explained 
Friends 2.947 73.7 
Romantic Partner 1.714 85.7 
Work 3.103 77.6 
School 2.641 66.0 
  
In sum, findings from the factor analyses conducted indicate that all questions in the 
CFDS contribute significant value to the measure and should be retained. Additionally, it seems 
that questions organize well into 4 subscales: Friends, Romantic Partner, Work, and School, with 
an Overall disclosure score. Thus, the Group subscales emerge as the “best” grouping method 
based on this criterion. 
Internal consistency. Internal consistency was used as a criterion for grouping methods, 
specifically Cronbach’s alpha values of 0.7 or greater. Based on this criterion, the Groups 
subscale was the best method, with α ranging from .71-.83. Findings are presented below in 
Tables 28 through 30. 
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Table 28. 
 
Cronbach’s alpha Values for the Groups Subscale 
 α α if item deleted 
Friends .818  
Do close friends know that you have CF?  .840 
Comfort in discussing CF experience with close friends.  .763 
Comfort in doing CF treatments in front of close friends.  .754 
Do casual friends know that you have CF?  .835 
Comfort in discussing CF with casual friends.  .743 
Comfort in doing CF treatments in front of casual friends.  .742 
Romantic Partner .713  
Does current romantic partner know that you have CF?  .886 
Comfort in discussing CF with current romantic partner.  .225 
Comfort doing CF treatments in front of current romantic partner.  .207 
Work .831  
Does current boss know that you have CF?  .866 
Comfort in discussing CF with current boss.  .772 
Comfort in doing CF treatments in front of current boss.  .757 
Do current coworkers know that you have CF?  .844 
Comfort in discussing CF with current coworkers.  .764 
Comfort in doing CF treatments in front of current coworkers.  .754 
School .780  
Do current teachers know that you have CF?  .796 
Comfort in discussing CF with current teachers.  .709 
Comfort in doing CF treatments in front of current teachers.  .722 
Do current classmates know that you have CF?  .786 
Comfort in discussing CF with current classmates.  .732 
Comfort in doing CF treatments in front of current classmates.  .687 
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Table 29. 
 
Cronbach’s alpha Values for the Type Subscale 
 α α if item deleted 
People Told .651  
Do close friends know that you have CF?  .650 
Do casual friends know that you have CF?  .571 
Does current romantic partner know that you have CF?  .765 
Does current boss know that you have CF?  .645 
Do current coworkers know that you have CF?  .527 
Do current teachers know that you have CF?  .543 
Do current classmates know that you have CF?  .533 
Comfort in Discussion -.040  
Comfort in discussing CF with close friends.  -.041 
Comfort in discussing CF with close friends.  .010 
Comfort in discussing CF with current romantic partner.  -.041 
Comfort in discussing CF with current boss.  -.435 
Comfort in discussing CF with current coworkers.  .183 
Comfort in discussing CF with current teachers.  -2.11 
Comfort in discussing CF with current classmates.  .394 
Comfort in Treatments .797  
Comfort in doing CF treatments in front of close friends.  .820 
Comfort in doing CF treatments in front of casual friends.  .852 
Comfort doing CF treatments in front of current romantic 
partner. 
 .820 
Comfort in doing CF treatments in front of current boss.  .674 
Comfort in doing CF treatments in front of current coworkers.  .737 
Comfort in doing CF treatments in front of current teachers.  .664 
Comfort in doing CF treatments in front of current classmates.  .719 
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Table 30. 
 
Cronbach’s alpha Values for the People Subscale 
 α α if item deleted 
Close Friends .657  
Do close friends know that you have CF?  .781 
Comfort in discussing CF experience with close friends.  .214 
Comfort in doing CF treatments in front of close friends.  .318 
Casual Friends .699  
Do casual friends know that you have CF?  .842 
Comfort in discussing CF with casual friends.  .256 
Comfort in doing CF treatments in front of casual friends.  .276 
Romantic Partner .713  
Does current romantic partner know that you have CF?  .886 
Comfort in discussing CF with current romantic partner.  .225 
Comfort doing CF treatments in front of current romantic partner.  .207 
Boss .599  
Does current boss know that you have CF?  .790 
Comfort in discussing CF with current boss.  .019 
Comfort in doing CF treatments in front of current boss.  .032 
Coworkers .689  
Do current coworkers know that you have CF?  .795 
Comfort in discussing CF with current coworkers.  .326 
Comfort in doing CF treatments in front of current coworkers.  .330 
Teachers .622  
Do current teachers know that you have CF?  .740 
Comfort in discussing CF with current teachers.  .125 
Comfort in doing CF treatments in front of current teachers.  .415 
Classmates .675  
Do current classmates know that you have CF?  .797 
Comfort in discussing CF with current classmates.  .316 
Comfort in doing CF treatments in front of current classmates.  .246 
 
Convergent validity. The People and Group subscale methods emerged as the “best” 
methods for this criterion. This determination was based on the People and Group subscales 
displaying basically equivalent effect sizes, and larger effect sizes (see Aim 3, pages 64-70) 
compared to the Group and Type of Disclosure subscales. People and Group subscale effect sizes 
ranged from .18 to .65 and .18 to .63, respectively. Type of Disclosure subscale effect sizes 
ranged from .18 to .27. 
The number of hypotheses supported, shown below in Table 31, also endorses the People 
subscale as the “best” method based on convergent validity. The People subscale also showed 
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the highest number of correlations with non-hypothesized factors (i.e., age and BMI), shown 
below in Table 32. However, this is likely due to the fact that the People subscale has the most 
subscales, and therefore the most hypotheses. 
Discriminant validity. The Type of Disclosure subscale method emerged as the “best” 
method for this criterion. This determination was based on the Type of Disclosure subscale 
displaying smaller effect sizes than the Group and People subscales. The Type of Disclosure 
subscale showed no significant findings with discriminant validity variables. The Group and 
People subscales showed individual highest effect sizes of .26 and .23, respectively. 
Based on the number of supported discriminant validity hypotheses, the Count Type and 
Risk Group emerge as the “best” subscales, shown below in Table 31 and 32. Table 33 
summarizes results for Aim 4 below; a checkmark indicates a “winner” for that criterion, while 
an “x” indicates the subscale method failed or was not the best method. 
Table 31. 
 
Hypothesized Correlations for All Subscale Types 
Hypothesized Outcomes Subscales 
 Count Group Count Type Count People Risk Group Risk People 
Convergent      
MOS-SS      
Emotional      
Social      
Respiratory      
Digestive      
CES-D      
CMPR      
Gender      
Illness severity      
Regimen complexity      
Discriminant      
CFKQ      
Insurance      
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Table 32. 
 
Non-Hypothesized Correlations for All Subscale Types 
Non-hypothesized 
Outcomes 
Subscales 
 Count Group Count Type Count People Risk Group Risk People 
Age      
BMI      
Self-efficacy      
 
Table 33. 
 
Aim 4 Summary Table 
Subscale Criterion 
 Data 
distribution 
Factor 
analyses 
Internal 
consistency 
Convergent 
validity 
Discriminant 
validity 
Group      
Type of 
Disclosure      
People      
 
Summary. In sum, no subscale grouping method produced evenly distributed data. The 
Group subscale method emerged as the best subscale grouping method based on the factor 
analysis and internal validity findings. The People and Group subscale had the highest 
convergent validity values than the Type of Disclosure grouping method. The Type of Disclosure 
subscale had lower discriminant validity values than any other subscale grouping method. 
Aim 5 
It was hypothesized that Cumulative Risk Coding would emerge as a better coding 
method for the CFDS. Findings will be presented in sections based on each criterion. 
Response distribution. As stated above in Aim 4, no coding method produced normally 
distributed results; thus, both coding methods “failed” this criterion. Refer to Figures 5-8 for 
more information. 
Convergent validity. The Count coding method had larger effect sizes compared to the 
Cumulative Risk subscale. The highest Count Group subscale effect size was .26, while the 
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highest Cumulative Risk Group effect size was .23. This information can be found in Aim 3, 
pages 64-70. However, correlations are too similar to conclusively nominate one coding method 
as the “best” method with only that information. On closer inspection, Count coding produced 
more hypothesized correlations than Cumulative Risk coding, indicating it is a better coding 
method. 
Discriminant validity. The Cumulative Risk coding method displayed smaller effect 
sizes (r = -.21) than the Count subscales (r = .26; r = -.46). Again, as above, these correlations 
are too similar to determine which method is best. Cumulative Risk coding had one less relation 
with discriminant validity variables than Count coding. 
Summary. The Count coding method tentatively emerged as the best subscale grouping 
method based on convergent and discriminant validity findings. Although Cumulative Risk 
coding produced lower discriminant validity values, it still had relations with those variables. 
Additionally, the Count coding method showed higher effect sizes with convergent validity 
variables than the Cumulative Risk coding method (.26 versus .23). Finally, Count coding 
produced many more correct hypotheses than the Cumulative Risk coding method, particularly 
in convergent validity sub-aims. 
Discussion 
 The aim of this study was to examine the validity of the CFDS, as well as to determine 
the best coding and grouping methods for the measure. Findings of all subscale grouping and 
coding methods for each aim will be briefly summarized. Count Group subscale findings will be 
expanded upon when appropriate, as this was determined to be the best coding and grouping 
method. Next, limitations of the current study will be addressed. Following this section, 
implications of the findings for psychological research and future directions are discussed. To 
close, clinical implications for psychological practice are detailed. 
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Aim 1 
This aim focused on scoring the CFDS according to three subscale grouping methods 
(e.g., Group, Type of Disclosure and People) and two coding techniques (Count and Cumulative 
Risk). No hypotheses were made in this research aim. While the data were being organized in 
this aim, it was discovered that the Type of Disclosure subscale grouping method was unable to 
be coded using the Cumulative Risk coding technique. Thus, all analyses were run only five 
times, instead of the planned six. The breadth of missing data also became clear during this aim; 
this will be discussed in the limitations section. 
Patterns of disclosure in our study replicate findings of previous research, with 
participants disclosing more frequently to close others (Modi et al., 2010). Equal comparisons 
cannot be made as groups were defined differently in the Modi et al. study; however, in general, 
it seems that rates of disclosure in the current study were slightly higher than prior findings. This 
may be due to the use of different instruments to collect disclosure data, or the way groups were 
defined in each survey. Additionally, the sample size of the Modi et al. study was nearly seven 
times higher than in this current study, likely because the survey was not part of a randomized 
controlled trial. This difference in sample size may influence findings and interpretation. 
Most participants in this sample had disclosed their CF diagnosis to Friends (87.5% 
compared to 81% in Modi et al.) and Romantic Partners (96.7% compared to 73% in Modi et 
al.), and felt highly comfortable discussing their CF and doing treatments in front of them. The 
next group to whom participants most frequently disclosed to was Work (70.9%; bosses and 
coworkers). Participants were moderately comfortable discussing their CF with this group, and 
less comfortable doing treatments in front of these people. Disclosure rates were lower for 
School (51.2%; teachers and classmates), but ratings of comfort in discussion and treatment were 
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approximately the same as the Work section. Differences between groups will be discussed 
further in Aim 3. 
Aim 2 
 This aim hypothesized that the CFDS would show significant differences when grouped 
by gender, illness severity, and regimen complexity. Specifically, it was posited that female 
participants, participants with more severe CF, and participants with more complex regimens 
would score higher on all subscales of the each subscale grouping method of the CFDS. 
This hypothesis was partially supported for gender groupings. Female participants 
disclosed more frequently and were more comfortable discussing and doing treatments with 
friends than male participants. Illness severity differences were partially supported only by risk 
coding. Participants with more severe CF disclosed more frequently at work, to bosses, and 
overall. No differences were found by regimen complexity. 
 Female participants’ higher levels of and comfort in disclosure is consistent with previous 
research in CF (Modi et al., 2010), which found that women with CF disclose more frequently 
and to more people than men with CF. Additionally, women generally access social support 
more readily, communicate more frequently, and use discussion as a coping mechanism more 
often than men (Ptacek, Smith, & Dodge, 1994; Tamres, Janicki, & Helgeson, 2002). This is a 
trend we see across health behaviors in that women are more likely than men to attend doctor’s 
appointments and communicate with physicians (Cleary, Mechanic, & Greenley, 1982; Krämer 
et al., 2012). 
Higher levels of disclosure at work by participants who are more severely ill aligns with 
prior research on worries about visibility. Adults with CF may disclose their diagnosis to address 
others’ concerns about highly noticeable symptoms such as weight loss or coughing (Modi et al., 
2010). Alternately, adults with CF in the workplace may be forced to disclose due to missed 
work as a result of a CF exacerbation. Although disclosure of a health condition at work is not 
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legally mandated, adults with more severe CF may choose to be proactive and disclose their CF 
before they have to miss work as a result of poor health. A qualitative study was conducted with 
adults who had disclosed their diabetes diagnosis at work (Ruston, Smith, & Fernando, 2013). 
Researchers found that participants felt their work superiors did not fully understand their 
disease, and they adjusted their disease management to fit the demands of their job, which often 
resulted in sub-optimal adherence and self-care behaviors. In CF, this may translate into adults 
skipping treatments in order to complete assignments or save time. 
Aim 3 
 This aim focused on convergent and discriminant validity of the CFDS using correlation 
analyses. Findings from this aim were also used to determine the best grouping and coding 
methods in Aim 4 and 5. 
 Social support. In the overall sample, the Count Friends, Count Close Friends, and 
Count Romantic Partner subscales were significantly associated with the social support. The 
People Told and Comfort in Discussion subscales were also significantly correlated with social 
support. Finally, the Risk Close Friends subscale and the Risk Overall Disclosure score were 
significantly associated with social support. These findings indicate that higher levels of social 
support were related to telling friends and romantic partners about their CF, feeling comfortable 
discussing their CF with these people, and feeling more comfortable doing treatments in front of 
these people. This is consistent with previous research indicating that adults with CF are most 
likely to disclose to close friends and romantic partners (Modi et al., 2010). These results also 
align with findings from HIV research, which indicates that disclosure may be a facet of social 
support, with people using disclosure to initially obtain social support (Maman, van Rooyen, & 
Groves, 2014) or strengthen existing relationships (Machtinger et al., 2015). 
 Emotional and social functioning. In the overall sample, the Friends subscale was 
positively associated with emotional and social functioning, suggesting that better emotional and 
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social functioning was associated with higher levels of disclosure to friends. The Close Friends, 
Comfort in Discussion, and Comfort in Treatments subscales, as well as the Overall Disclosure 
score, were positively associated with the Social Functioning subscale, indicating that better 
social functioning was associated with higher levels of overall disclosure and greater comfort in 
discussion and completion of treatments in front of others. The Count Close Friends subscale 
was positively associated with both subscales. No significant correlations were found with Risk 
subscales. These findings are consistent with cancer research, which found that participants who 
are healthy emotionally and have a more robust social network share their health experiences 
with friends and family (Ringdal, Ringdal, Jordhøy, & Kaasa, 2007). Additionally, McHugh and 
colleagues (2015) found that active coping styles in adults with CF, which may include 
behaviors like discussing CF challenges with close friends, were related to better social and 
emotional functioning as measured by the CFQ-R. 
 Respiratory and digestive symptoms. In the overall sample, the Overall Disclosure 
score was positively associated with respiratory symptoms and digestive symptoms. No 
significant correlations were found with Type of Disclosure subscales or any Risk subscales. 
This suggests that participants experiencing fewer respiratory and digestive symptoms are more 
likely to disclose overall. This is the opposite of our hypothesis and inconsistent with 
correlations founds in this study between lung function and disclosure. These findings may 
indicate that the experience of symptoms does not lead to disclosure and disclosure does not lead 
to changes in health outcomes. 
 Depression. The Comfort in Discussion subscale was inversely correlated with 
depression, indicating that participants who feel more comfortable discussing their CF with 
others display fewer depressive symptoms. No significant associations were found with 
depression in any other subscales. If disclosure is considered to be an aspect of social support, 
this finding seems to partially support associations found between social support and depression 
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in people with chronic illness in previous studies (Mohr, Classen, & Barrera, 2004; Sacco & 
Yanover, 2006; Whatley, Dilorio, & Yeager, 2010). It could be that, beyond discussion with 
others, facets of disclosure capture a distinct construct not included in social support, and 
therefore do not correlate with depression. Additionally, depression has a strong biological 
component (Krishnan & Nestler, 2010) that may be unaffected by disclosure. Thus, disclosure 
alone may not alleviate symptoms of depression, and depressive symptoms may not impact 
disclosure. 
 Self-efficacy. In the overall sample, self-efficacy was positively related to the Count 
Close Friends, Count Casual Friends, Count Friends, Count People Told subscales, and Count 
Overall disclosure score. Self-efficacy was inversely associated with the Risk Close Friends, 
Risk Casual Friends, Risk Friends, Risk Coworker, Risk Work, Risk Teacher, Risk Classmates, 
Risk School subscales, and Risk Overall disclosure score. This indicates that higher levels of 
disclosure are associated with greater self-efficacy. The numerous correlations between Risk 
subscales and self-efficacy indicates that the Risk coding method facilitates a unique relation 
between disclosure and self-efficacy not present in the traditional Count coding method. 
There is currently no research examining disclosure and self-efficacy in CF. Self-efficacy 
has been linked to disclosure in the HIV-literature, along with sexual behavior and adherence 
(Houston et al., 2015; Kalichman & Nachimson, 1999), with higher self-efficacy related to more 
frequent disclosure, better adherence, and safer sex practices. If people with CF are comfortable 
disclosing and discussing their CF, it reduces adherence barriers. Subsequently, people with CF 
may feel more comfortable that they can complete their CF treatments in a variety of 
environments, including in front of others. 
 Adherence. In the overall sample, the Risk Teachers, Risk Classmates, and Risk School 
subscales were negatively related to adherence, which means that higher levels of disclosure in 
school were related to better adherence. This finding may not indicate a direct association 
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between disclosure and adherence, as one study showed that adherence to nebulized medications 
was best on school days in adolescents with CF due to school day routines (Ball, Southern, 
McCormack, Duff, Brownlee, & McNamara, 2013). Additionally, meetings with a school nurse 
to obtain enzymes or nebulized treatments may be built into the students’ day, ensuring 
adherence as long as the student attends the meeting. Alternately, a greater proportion of 
participants in school may still live at home, which could facilitate greater parental involvement 
in adherence. 
 While no quantitative studies have examined adherence and disclosure in CF, disclosure 
and embarrassment in doing treatment in front of others has been named as a barrier and 
facilitator to adherence in a previous qualitative study of adults with CF (Rand-Giovanetti et al., 
2010; George et al. 2010). Findings from the current study may suggest that general disclosure 
outside of a school setting does not impact adherence. While it is important for children with 
chronic illness to have parental monitoring and teacher assistance, findings from this study may 
indicate a greater emphasis be placed on self-reliance in adulthood for the concrete tasks 
associated with adherence, as they are fully responsible for their own care. 
 Non-hypothesized correlations. Age was significantly negatively associated with the 
Count Close Friends, Count Casual Friends, and Count Friends subscales, as well as the Count 
Overall Disclosure score. Age was significantly positively associated with the Risk Teachers, 
Risk Classmates, and Risk School subscales. These findings indicate that older participants were 
less likely to disclose to friends, teachers, or classmates. This may reflect parents telling their 
child’s school staff about their CF, which leads to higher disclosure scores among participants 
still in school. Additionally, older participants access a wider variety of learning formats (e.g., 
online, community college) which have less of a “family” environment which facilitates personal 
disclosures. However, the association between disclosure to friends and age somewhat 
contradicts expected results. Since age is associated with more severe disease in CF, it stands to 
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reason that age would be associated with higher levels of disclosure due to increased visibility of 
symptoms. 
 BMI was significantly positively associated with Risk Teachers, Risk Classmates, and 
Risk School subscales, indicating that participants with higher BMIs were more likely to disclose 
to teachers and classmates. Similar to correlations found with age, this association is not what 
would be expected. Lower BMI is associated with more severe disease in CF (Stephenson et al., 
2013), and it would be expected that patients would disclose more frequently with low BMIs. 
Findings from this study may be explained by the visibility of CF symptoms and treatments. 
Even with mild disease, CF treatments (e.g., CPT methods, enzymes) are highly visible. Thus, 
differences may not be seen in people with CF based on illness severity. 
Aim 4 
 This aim focused on determining the “best” subscale grouping method for the CFDS. 
Information from data distribution, factor analyses, internal consistency, and convergent and 
discriminant validity results were used to evaluate each subscale grouping method’s worth. 
Findings will be summarized and discussed below. 
CFDS data were plotted into graphs organized by subscale grouping methods. No 
subscale grouping method produced normally distributed data, so all subscale grouping methods 
“failed” this criterion. Although factor analysis indicated that all questions added value to the 
measure, further analyses were only able to be performed for the Group subscale due to missing 
or not applicable data. These factor analyses indicated that the CFDS questions strongly loaded 
onto the Group subscales. Thus, the Group subscale grouping method was determined to be the 
“best” method for this criterion. Internal consistency results showed that the Group subscale 
produced the highest Cronbach’s alpha values, again showing that the Group subscale was 
superior to other subscale grouping methods. 
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 Convergent validity analyses indicated that the People subscale had higher convergent 
validity values than any other subscale grouping method. However, this is likely due to the 
People subscale simply having more hypotheses in this aim due to the larger number of subscales 
in this grouping method. This is also why the People subscale had the highest number of correct 
hypotheses. The People subscale also had the highest number of discriminant validity 
correlations. Discriminant validity analyses showed the Type of Disclosure subscale had lower 
discriminant validity values compared to any other subscale grouping method. However, it also 
had the lowest number and strength of convergent validity correlations. Given the number of 
correlations displayed by each subscale grouping method, all approaches had good evidence of 
discriminant validity. 
 When examined as percentages, the Group subscale had 42% correct hypotheses, the 
Type of Disclosure subscale had 62% correct hypotheses, and the People subscale had 41% 
correct hypotheses. Using this method, the Type of Disclosure subscale was the best subscale for 
overall validity analyses. 
 Examining all Aim 4 results together, the Group subscale emerged as the best subscale 
grouping method. It was determined to be the best by two sub-aims, while the Type of 
Disclosure and People subscales were superior in one sub-aim each. Additionally, factor analysis 
is the “gold standard” method of assessing validity; no subscale method would be acceptable 
without those results. Since factor analysis was only able to be run on the Group subscale, and 
also indicated its structure and distribution were sound, the Group subscale is the only viable 
subscale grouping option for the CFDS. 
Aim 5 
 This aim focused on determining the “best” coding method for the CFDS. Information 
from data distribution and convergent and discriminant validity results were used to evaluate 
each subscale coding method’s worth. Findings will be summarized below, then discussed. 
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 As discussed previously for Aim 4, no coding method produced data which were 
normally distributed. Thus, both coding methods “failed” this criterion. The Count coding 
method emerged as the “best” coding method on the basis of convergent validity effect sizes. 
Count coding subscales displayed stronger relationships with convergent validity study variables 
than Cumulative Risk subscales. Additionally, Count coding was more likely to be associated 
with social support and social and emotional functioning. The Cumulative Risk coding method 
emerged as the “best” coding method on the basis of discriminant validity effect sizes. 
Cumulative Risk subscales displayed weaker relationships with discriminant validity variables 
than Count subscales. Cumulative Risk coding was more likely to be associated with self-
efficacy. 
 No definitive “best” coding method emerged from these analyses. However, when 
examined more closely, findings support the Count coding method as superior. First, it has 
robust relationships with convergent validity variables. Second, while Cumulative Risk coding 
had lower effect sizes for discriminant validity analyses, the difference was only .03, which is 
statistically and clinically negligible. Finally, Count coding produced many more correct 
hypotheses than the Cumulative Risk coding method, particularly in convergent validity sub-
aims. Count coding hypotheses were 50% correct, compared to 37% percent correct for Risk 
coding hypotheses. 
Limitations and Future Directions 
 This section discusses several factors which should be considered when interpreting 
results of this study. These areas will be discussed in the context of future research directions as 
well. 
 Missing data. As previously mentioned, missing data were the primary limitation of this 
study. The CFDS is organized so that if participants have not informed someone about their 
diagnosis, they skip subsequent questions about disclosure. For example, if a participant had not 
 
 
93 
disclosed his or her CF diagnosis to their romantic partner, the participant was instructed to skip 
to the next set of questions. Additionally, if a participant did not have a romantic partner, did not 
work, or was not in school, they were instructed to skip the next section. This has an advantage 
in that only concrete experiences are recorded, and speculated or imagined situations are not 
considered. It would be difficult for a participant to imagine their comfort in discussing CF or 
doing treatments in front of others when they have never done so. 
However, this questionnaire structure resulted in many skipped questions and a large 
amount of missing data. The School section was the least answered area in the CFDS, mostly due 
to the majority of participants having finished their education. A better strategy may have been to 
ask them to think about a time when they had told someone in that area about their CF, and 
answer questions based on that experience. Using that method, many participants may have been 
able to answer the School or Romantic Partner sections based on previous situations. Alternately, 
the School section could only be selectively administered in research when there is a large 
enough sample to avoid statistical error. 
Alternately, participants could skip subsequent questions if necessary, but be given a 
response option to explain why they had not told that particular person about their CF. A range 
of responses would be possible, from “it’s too early in the relationship” to “I am afraid of 
negative repercussions” to “I don’t want to answer this question.” These qualitative responses 
could be interpreted as-is, or be coded according to common themes and analyzed quantitatively. 
Future applications of the CFDS should add a response box asking “why or why not?” 
after each “does X know that you have CF” question. Respondents would be asked to detail why 
they have or have not told the person in that category that they have CF. The qualitative 
information gathered from the extra question could simply serve to add more detail and context 
to the questionnaire and any missing data patterns. However, it could also be coded into discrete 
categories during another validation study, and the most common answers could be added as 
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automatic response options to the “why or why not” question in order to streamline the 
questionnaire for all qualitative information. 
Another missing data issue was that household income was only collected on half of 
participants. A question assessing for annual household income was added halfway through the 
study, so this information was gathered for only 50.4% of the sample. With a sample size of 50, 
often dropping lower in certain disclosure categories, the statistical power of analyses is sharply 
limited. It will be important for future studies with the CFDS to gather complete household 
income data in order to verify findings from this study. 
A final issue with missing data was related to the regimen complexity calculation. The 
full regimen complexity score was unable to be calculated, as complete medical information was 
unavailable for all participants; thus, a partial regimen complexity score was calculated with 
available information. Findings of t-tests grouped by regimen complexity should be interpreted 
with extreme caution due to the inability to calculate the full regimen complexity score. Data 
were only collected regarding a restricted range of medications. Information such as chest 
physiotherapy frequency, enzyme dosage or prescription, and prescription of any non-CF 
specific medications, was not collected. 
Future research should gather complete medical data on participants in order to compute 
a complete regimen complexity score. The number of prescribed medications and treatments 
(e.g., regimen complexity) generally increases along with the visibility of symptoms. This could 
have implications for disclosure behavior. As discussed earlier in this manuscript, some 
participants may feel compelled to disclose due to severe, frequent symptoms, while others may 
choose to attribute symptoms to a cold or respiratory infection without mentioning CF. However, 
CF symptoms and treatments can be visible even in participants with mild illness severity, which 
may render illness severity moot with regard to disclosure. 
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 Sample size. Sample size could also be considered a limitation of the current study. The 
general rule for sample size in factor analysis is five to ten cases for each question, with larger 
sample sizes displaying greater statistical power (Tinsley & Tinsley, 1987). With 21 questions, 
acceptable sample sizes would range from 105 to 210. While a sample size of 129 is acceptable 
based on this guideline, the number of participants was far less in some groups due to missing 
data. 
 Future research should distribute the CFDS along with other demographic and 
psychosocial measures in a cross-sectional, multicenter study. A larger, more diverse sample 
would aid in interpretation of results and allow researchers to learn more about underpowered 
groups in this sample, such as ethnic minorities and participants in school. 
Clinical Implications 
 Overall, it appears that participants are most likely to tell close others about their CF, 
perhaps based on relationship building through disclosure and trust. Subsequently fewer numbers 
disclose to teachers and bosses, although these levels of disclosure were still higher than in 
previous research. It will be important for future research to gather more information regarding 
people’s choice to disclose or not, as discussed above. With that information, the impact of 
disclosure can be truly assessed for clinical utility. 
 Disclosures to friends in this sample was associated with greater social support, better 
social and emotional functioning, and increased self-efficacy. Clinicians should discuss 
disclosure with individuals with poor psychosocial functioning, as disclosing to others may help 
alleviate feelings of isolation and increase social support. Assessing a patient’s self-efficacy and 
disclosure practices may guide clinicians in potential interventions for their patients. 
This study showed low levels of disclosure to bosses or teachers. This may be due to less 
time spent in those environments and/or less intimacy in those relationships. It may be helpful, 
however, to address those disclosure situations with patients. CF can significantly impact time 
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away from school or work as a result of exacerbations. Patients may find it helpful to address 
potential issues with bosses or teachers before they occur. Additionally, with high rates of 
infertility due to CF, patients may want to discuss strategies of disclosing their diagnosis in the 
context of romantic relationships. Disclosing CF to a significant other at any point during the 
relationship can be stressful, and explaining the impact of the disease on life expectancy and 
pregnancy can be even more difficult. Future research may choose to explore specific topics of 
disclosure, such as family planning, in adults with CF. 
 Notable differences were found between male and female participants. It appears that 
disclosure is related to significantly more psychosocial variables for males than for females. This 
may be related to differences in patterns of communication between genders; women tend to be 
more verbal and are more likely to access social support to cope than men. Disclosure may serve 
on the spectrum of these coping behaviors. For instance, when men engage in disclosure 
behaviors, it may be more meaningful for them than more women, who display these coping or 
communication behaviors more frequently and indiscriminately. This information is important in 
a clinical setting. These findings may reflect typical gender-based friendships, where men make 
fewer personal disclosures than women. If men are only disclosing to very close others (friends 
and romantic partners), clinicians should assess for overall emotional and social functioning, and 
focus on other important clinical issues if results indicate no significant difficulties in this 
domain. 
 More research is needed before the CFDS can be used in practice. Based on findings 
from this study, it appears that the CFDS is most valuable when divided into sections of Friends, 
Romantic Partner, Work, and School, with responses added to obtain scores in those areas. An 
overall sum of the CFDS indicates the patient’s overall level of disclosure across groups. Mental 
health professionals will benefit from any further research with the CFDS, whether it is in the 
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course of validation studies, or examining relations between disclosure and other psychosocial 
variables. 
Summary 
 The current study sought to validate a new questionnaire assessing disclosure in older 
adolescents and adults with CF, the CFDS. The study had five aims: (1) score the CFDS 
according to three subscale grouping methods and two coding techniques, (2) use known groups 
validation to establish psychometric properties of three subscale grouping methods, (3) 
determine convergent and discriminant validity of the three subscale grouping and two coding 
methods, (4) identify the “best” subscale grouping method, and (5) identify the “best” coding 
strategy. 
 Results aligned with prior research in disclosure in CF, with participants disclosing most 
often to close others and less often at school or in the workplace. Disclosure to close and casual 
friends was consistently associated with better psychosocial functioning. Factor analyses 
determined the CFDS was valid and that all questions should be retained. The Count Group 
subscale also emerged as the “best” subscale grouping and coding method. This study 
contributed to the literature by serving as the first validation study of a questionnaire of 
disclosure in CF. Additionally, as disclosure in CF is a new emerging area, this study added 
information to the sparse literature on this issue. 
 Findings from this study and complex missing data patterns suggest that more research is 
needed in disclosure in CF. A qualitative question should be added to the CFDS to gather 
information about why or why not participants disclose their CF to others. As is traditional in 
validation of studies, a large-scale dissemination of the CFDS to an adult CF population is 
warranted to verify findings from this initial study, as well as to gain more information about 
disclosure in CF. In particular, an attempt should be made to gather full medication and 
household income information from participants, as well as include ethnic minorities with CF in 
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any future studies. Ultimately, the CFDS as it exists now gathers important research and clinical 
information from adults with CF, and should be examined further with a larger sample size and 
more descriptive information. 
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Appendix A 
 
Disclosure Questionnaire 
 
 
 
 
 
People with CF have different groups of people that they may feel comfortable informing about their diagnosis. We 
want to know which people in your life know about your CF. For the questions below, please indicate whether all, some, 
or none of each of these groups know that you have CF.   
 
For those groups of people who know about your CF, we would like to know how comfortable you are discussing your CF 
with them and doing your treatments* in front of them. On a scale of 1 to 10, where 1 is not at all comfortable, 10 is 
completely comfortable, and 5 is somewhere in between (somewhat comfortable), please indicate how comfortable you 
are engaging in the following CF-related activities with the specified audience.   
 
If you have never been in a position where you needed to do your treatments in front of a particular group, please 
choose your answer by thinking about how you might feel in this situation. Remember, there are no right or wrong 
answers to these questions. 
 
*For these questions, we are only referring to the following medications: Pulmozyme, TOBI, Hypertonic Saline, 
and/or Azithromycin. 
 
FRIENDS 
 
189. Do your close friends know that you have CF? 
 Yes, all of them. 
 Yes, some of them. 
 No, none of them. (SKIP TO QUESTION 240) 
 
Rate your overall comfort in…  
1 2 3 4 5 6 7 8 9 10 
Not at all 
comfortable 
 
Somewhat 
comfortable 
 
Completely 
comfortable 
190. …discussing your CF experience with your close 
friends. 
          
191. …doing your CF treatments in front of your close 
friends. 
          
 
 
192. Do your casual friends /acquaintances know that you have CF? 
 Yes, all of them. 
 Yes, some of them. 
 No, none of them. (SKIP TO QUESTION 243) 
 
 
 
Rate your overall comfort in…  1 2 3 4 5 6 7 8 9 10 
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Not at all 
comfortable 
 
Somewhat 
comfortable 
 
Completely 
comfortable 
193. …discussing your CF experience with your casual friends or 
acquaintances. 
          
194. …doing your CF treatments in front of your casual friends or 
acquaintances. 
          
 
SPOUSE/ROMANTIC PARTNER 
 
195. Does your current spouse/romantic partner know that you have CF? 
 Yes 
 No (SKIP TO QUESTION 247) 
 I do not have a spouse/romantic partner. (SKIP TO QUESTION 246) 
 
Rate your overall comfort in…  
1 2 3 4 5 6 7 8 9 10 
Not at all 
comfortable 
Somewhat 
comfortable 
Completely 
comfortable 
196. …discussing your CF experience with your current 
spouse/romantic partner. 
          
197. …doing your CF treatments in front of your current spouse/romantic 
partner. 
          
 
WORKPLACE 
 
198. Does your current boss know that you have CF? 
 Yes 
 No  (SKIP TO QUESTION 249) 
 I am not currently working. (SKIP TO QUESTION 252)  
 
Rate your overall comfort in… 
1 2 3 4 5 6 7 8 9 10 
Not at all 
comfortable 
 
Somewhat 
comfortable 
 
Completely 
comfortable 
199. …discussing your CF experience with your current 
boss. 
          
200. …doing your CF treatments in front of your current 
boss. 
          
 
201. Do your current coworkers know that you have CF?  
 Yes, all of them. 
 Yes, some of them. 
 No, none of them. (SKIP TO QUESTION 253) 
 
Rate your overall comfort in… 
1 2 3 4 5 6 7 8 9 10 
Not at all 
comfortable 
 
Somewhat 
comfortable 
 
Completely 
comfortable 
202. …discussing your CF experience with your current 
coworkers. 
          
203. …doing your CF treatments in front of your current 
coworkers.  
          
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SCHOOL 
 
204. Do your current teachers know that you have CF? 
 Yes, all of them. 
 Yes, some of them. 
 No, none of them. (SKIP TO QUESTION 255) 
 I am not currently a student. (SKIP TO QUESTION 258)  
 
Rate your overall comfort in…  
1 2 3 4 5 6 7 8 9 10 
Not at all 
comfortable 
 
Somewhat 
comfortable 
 
Completely 
comfortable 
205. …discussing your CF experience with your current 
teachers. 
          
206. …doing your CF treatments in front of your current 
teachers. 
          
 
207. Do your current classmates know that you have CF? 
 Yes, all of them. 
 Yes, some of them. 
 No, none of them. (SKIP TO QUESTION 258) 
 
Rate your overall comfort in…  
1 2 3 4 5 6 7 8 9 10 
Not at all 
comfortable 
 
Somewhat 
comfortable 
 
Completely 
comfortable 
208. …discussing your CF experience with your current 
classmates. 
          
209. …doing your CF treatments in front of your current 
classmates.  
          
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Appendix B 
 
Medical Outcome Study Social Support Survey 
 
 
 
 
People sometimes look to others for companionship, assistance, or other types of support.  
Circle one number for each item. 
 
How often is each of the following kinds of support available to you if you need it? 
N
o
n
e
 o
f 
th
e
 t
im
e
 
A
 li
tt
le
 o
f 
th
e
 t
im
e
 
So
m
e
 o
f 
th
e
 t
im
e
 
M
o
st
 o
f 
th
e
 t
im
e
 
A
ll 
o
f 
th
e
 
ti
m
e
 
189. Someone you can count on to listen to you when you need to talk.      
190. Someone to give you information to help you understand a situation.      
191. Someone to give you good advice about a crisis.      
192. Someone to confide in or talk to about yourself or your problems.      
193. Someone whose advice you really want.      
194. Someone to share your most private worries and fears with.      
195. Someone to turn to for suggestions about how to deal with a personal 
problem. 
     
196. Someone who understands your problems.      
197. Someone to help you if you were confined to bed.      
198. Someone to take you to the doctor if you needed it.      
199. Someone to prepare your meals if you were unable to do it yourself.      
200. Someone to help you with daily chores if you were sick.      
201. Someone who shows you love and affection.      
202. Someone to love you and make you feel wanted.      
203. Someone who hugs you.      
204. Someone to have a good time with.      
205. Someone to get together with for relaxation.      
206. Someone to do something enjoyable with.      
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How often is each of the following kinds of support available to you if you need it? 
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207. Someone to do things with to help you get your mind off things.      
 
   
 
117 
 
 
 
 
 
Appendix C 
 
CES-D 
 
 
 
 
For the following 20 items please select the choice that best 
describes how YOU have felt over the past week: 
Rarely or 
None of 
the Time  
(Less than 
1 Day) 
Some or 
Little of 
the Time  
(1-2 Days) 
Occasionally 
or a 
Moderate 
Amount of 
the Time  
(3-4 Days) 
Most or 
All of the 
Time (5-7 
Days) 
94.  I was bothered by things that usually don’t bother me.     
95. I did not feel like eating; my appetite was poor.     
96. I felt that I could not shake off the blues even with help 
from my family and friends. 
    
97. I felt that I was just as good as other people.     
98. I had trouble keeping my mind on what I was doing.     
99. I felt depressed.     
100. I felt that everything I did was an effort.     
101. I felt hopeful about the future.     
102.  I thought my life had been a failure.     
103. I felt fearful.     
104. My sleep was restless.     
105. I was happy.     
106. I talked less than usual.     
107. I felt lonely.     
108. People were unfriendly.     
109. I enjoyed life.     
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110. I had crying spells.     
111. I felt sad.     
112. I felt that people disliked me.     
188.       I could not “get going.”       
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Appendix D 
 
CFQ-R:  Cystic Fibrosis Questionnaire 
Adolescents and Adults (Patients 14 Years Old and Older) 
 
 
 
 
Understanding the impact of your illness and treatments on your everyday life can help your healthcare team keep 
track of your health and adjust your treatments. For this reason, this questionnaire was specifically developed for 
people who have cystic fibrosis. Thank you for your willingness to complete this form. 
 
Instructions:   The following questions are about the current state of your health, as you perceive it. This information 
will allow us to better understand how you feel in your everyday life. Please answer all the questions. There are no 
right or wrong answers! If you are not sure how to answer, choose the response that seems closest to your situation. 
 
SECTION I. DEMOGRAPHICS 
Please fill in the information or check the box indicating your answer.  
 
1. What is your date of birth? 
 
Date         
 Mo Day Year 
 
2. What is your gender? 
 
  Male      Female 
 
3.  During the past two weeks, have you been on 
vacation or out of school or work for reasons 
NOT related to your health? 
  
 Yes      No 
 
4. What is your current marital status? 
 
  Single/never married 
  Married 
  Widowed 
  Divorced 
  Separated 
  Remarried  
  With a partner 
 
5. Which of the following best describes your 
racial background? 
 
  Caucasian 
  African American 
  Hispanic 
  Asian/Oriental or Pacific Islander 
  Native American or Native Alaskan 
  Other (please describe) _____________ 
  Prefer not to answer this question 
 
 
 
 
 
6. What is the highest grade of school 
you have completed? 
 
 Some high school or less 
 High school diploma/GED 
 Vocational school 
 Some college 
 College degree 
 Professional or graduate degree  
 
7.   Which of the following best describes 
your current work or school status? 
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 Attending school outside the home 
 Taking educational courses at home 
 Seeking work 
 Working full or part time (either outside the 
home or at a home-based business) 
 Full time homemaker 
 Not attending school or working due to my 
health  
 Not working for other reason 
 
 
 
 
 
 
SECTION II.  QUALITY OF LIFE 
Please check the box indicating your answer. 
 
During the past two weeks, to what extent have you had difficulty…? 
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8. …performing vigorous activities such as running or playing sports.     
9. …walking as fast as others.     
10. …carrying or lifting heavy things such as books, groceries, or school bags.     
11. …climbing one flight of stairs.     
12. …climbing stairs as fast as others.     
During the past two weeks, indicate how often… Always Often Sometimes Never 
13. …you felt well.     
14. …you felt worried.     
15. …you felt useless.     
16. …you felt tired.     
17. …you felt energetic.     
18. …you felt exhausted.     
19. …you felt sad.     
 
Please select the box indicating your answer. Please choose only one answer for each question. 
 
Thinking about the state of your health over the last two weeks… 
20. To what extent do you have difficulty walking? 
 You can walk a long time without getting tired. 
 You can walk a long time but you get tired. 
 You cannot walk a long time because you get tired quickly. 
 You avoid walking whenever possible because it is too tiring for you. 
21. How do you feel about eating? 
 Just thinking about food makes you feel sick. 
 You never enjoy eating. 
 You are sometimes able to enjoy eating. 
 You are always able to enjoy eating. 
 
 
22. To what extent do your treatments make your daily life more difficult?  
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 Not at all 
 A little 
 Moderately 
 A lot 
 
23. How much time do you currently spend each day on your treatments? 
 A lot 
 Some 
 A little 
 Not very much  
 
24. How difficult is it for you to do your treatments (including medications) each day? 
 Not at all 
 A little 
 Moderately 
 Very 
25. How do you think your health is now? 
 Excellent 
 Good 
 Fair 
 Poor 
 
 
Please select a box indicating your answer. 
 
Thinking about your health during the past two weeks, indicate the extent 
to which each sentence is true or false for you. 
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26. I have trouble recovering after physical effort.     
27. I have to limit vigorous activities such as running or playing sports.     
28. I have to force myself to eat.     
29. I have to stay at home more than I want to.     
30. I feel comfortable discussing my illness with others.     
31. I think I am too thin.     
32. I think I look different from others my age.     
33. I feel bad about my physical appearance.     
34. People are afraid that I may be contagious.     
35. I get together with my friends a lot.     
36. I think my coughing bothers others.     
37. I feel comfortable going out at night.     
38. I often feel lonely.     
39. I feel healthy.     
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40. It is difficult to make plans for the future (for example, going to 
college, getting married, advancing in a job, etc.). 
    
41. I lead a normal life.     
 
SECTION III. SCHOOL, WORK, OR DAILY ACTIVITIES 
Questions 43 through 46 are about school, work, or other daily tasks. 
 
42.  To what extent did you have trouble keeping up with your schoolwork, professional work, or other daily 
activities during the past two weeks?  
 You have had no trouble keeping up. 
 You have managed to keep up but it has been difficult. 
 You have been behind. 
 You have not been able to do these activities at all. 
 
 
 
Always Often Sometimes Never 
43. How often were you absent from school, work, or 
unable to complete daily activities during the last two 
weeks because of your illness or treatments? 
    
44. How often does CF get in the way of meeting your 
school, work, or personal goals? 
    
45. How often does CF interfere with getting out of the 
house to run errands such as shopping or going to the 
bank? 
    
 
SECTION IV. SYMPTOM DIFFICULTIES 
Please select a box indicating your answer. 
 
During the past two weeks: A great deal Somewhat A little Not at all 
46. Have you had trouble gaining weight?     
47. Have you been congested?     
48. Have you been coughing during the day?     
49. Have you had to cough up mucus?     
 
(Skip to Question 51 if you answered Question 49 “Not at all”) 
 
50. Has your mucus been mostly…? 
 Clear 
 Clear to yellow 
 Yellowish-green 
 Green with traces of blood 
 Do not know 
 
How often during the past two weeks: Always Often Sometimes Never 
51. Have you been wheezing?     
52. Have you had trouble breathing?     
53. Have you woken up during the night because you were 
coughing? 
    
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54. Have you had problems with gas?     
55. Have you had diarrhea?     
56. Have you had abdominal pain?     
57. Have you had eating problems?     
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Appendix E 
 
Self-Efficacy 
 
 
 
 
 
For the following questions, we are only referring to the following medications: Pulmozyme, TOBI, 
Hypertonic Saline, and/or Azithromycin. 
 
There are many situations in which it is difficult for people to take their pulmonary CF medications. On a scale 
of 1 to 10, where 1 is not at all sure, 10 is completely sure, and 5 is somewhere in between (somewhat sure), 
please indicate how sure you are that you can do your CF treatments the way your doctor told you to in these 
situations. Remember, there are no right or wrong answers to these questions. 
 
 
How sure are you that you can do your CF treatments the 
way the doctor said… 
1 2 3 4 5 6 7 8 9 10 
Not at all 
sure 
 Somewhat sure  
Completel
y sure 
94. …when you are in a hurry?           
95. …when you do not feel like doing them?           
96. …when you are tired or sleepy?           
97. …when you want to do something else?           
98. …if nobody reminds you to do it?           
99. …when you do not have a private place to do 
them? 
          
100. …when you feel fine or have no symptoms?           
101. …when your friends are around?           
102. …when your family members are around?            
103. …when you are around people you do not know 
well? 
          
104. …when you are in the middle of doing something 
else?  
          
105. …when they take too long?           
106. …on work / school days?           N/A 
107. …on weekends?           
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108. …when nobody is around to notice?           
109. …when a romantic partner is around?           N/A 
110. …when you are in a bad mood?           
111. …when you are sick?           
112. …every day?           
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Appendix F 
 
CF Knowledge Questionnaire 
 
 
 
 
Please read each question carefully and then circle the correct answer. 
58.  CF primarily affects the: 
a. lungs 
b. stomach 
c. heart 
d. liver 
 
59.  Digestion of starches or carbohydrates begins in the: 
a. stomach 
b. intestines 
c. liver 
d. mouth 
 
60.  The most important physical symptom that tells you how your body is working is: 
a. mood 
b. hair loss 
c. appetite 
d. cough 
 
61.  Airway clearance means: 
a. removing mucus from your lungs 
b. shaking the mucus in your lungs 
c. exercising more 
 
62.  Which foods cannot be properly digested without enzymes? 
a. Foods high in fat such as butter and peanut butter. 
b. Foods high in protein such as chicken. 
c. Foods high in carbohydrates such as bread. 
d. All of the above. 
e.    A and b only 
 
63.  If you are not digesting fat from food, your stools will: 
a. sink 
b. float 
c. be greasy 
d. b and c 
e. None of the above. 
 
 
64.  If you get a lung infection, you will have: 
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a. less energy 
b. more coughing 
c. more and darker mucus 
d. all of the above 
 
65.  The foods that contain the most energy / calories are: 
a. fats 
b. carbohydrates 
c. proteins 
 
66.   TOBI (inhaled tobramycin) is used to: 
a. prevent the flu that people often catch during cold weather. 
b. treat a bacteria called methicillin-resistant staph aureus (MRSA). 
c. treat a bacteria called pseudomonas aeruginosa. 
d. open airways and assist in coughing up mucus. 
e. none of the above. 
 
67. The CF Foundation recommends that people with CF eat about: 
a. 125-150% of the recommended amount of foods for people without CF. 
b. the same amount of food as people without CF. 
c. less food than people without CF. 
d. twice as many fruits and vegetables as people without CF. 
e. a and d. 
 
68.  People with CF take vitamins A, D, E, and K because: 
a. they are often poorly absorbed 
b. they need extra water to be absorbed 
c. there is not enough of these vitamins in foods people normally eat 
d. a and c. 
 
69. Which statement is true? 
a. Enzymes are effective as long as they are taken no more than 1 hour before starting a meal. 
b. Enzymes are effective as long as they are taken no more than 1 hour after a meal. 
c. If a person takes more than 30 to 40 minutes to eat a meal, more enzymes should be given.  
d. All of the above. 
e. None of the above. 
 
70. Which meal would give a person with cystic fibrosis more energy? 
a. Broiled chicken breast with skin removed, salad with 1 teaspoon dressing, baked potato 
with 1 teaspoon butter, 1 can of soda. 
b. Grilled cheese sandwich with 2 slices of cheese grilled in 2 tablespoons butter, 3 ounces of 
potato chips, milkshake. 
c. Bowl of 1 cup of cheerios with ½ cup whole milk, two pieces of white toast with 1 teaspoon 
butter, 1 cup orange juice. 
 
71.  The most serious problem resulting from having CF is: 
a. repeated lung infections 
b. having to take enzymes 
c. gas 
d. being smaller than others the same age 
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72.   It is OK to keep enzymes: 
a. in the original medicine bottle in the glove compartment of your car. 
b. in a ziplock bag in your pocket. 
c. in the original medicine bottle on top of the microwave. 
d. All of the above. 
e. None of the above. 
 
73.  Which of the following statements is true? 
a. the person with CF needs antibiotics only when suffering from a fever 
b. antibiotics can be stopped as soon as a person is feeling better 
c. antibiotics will help prevent catching a cold 
d. antibiotics help treat lung infections 
e. b, c, and d 
 
74. Exercise, especially in the summer, can cause a decrease in the level of __________ in your body. 
a. salt  
b. water 
c. both salt and water 
d. enzymes 
e. all of the above 
 
75.  Most of the food you eat is absorbed in the: 
a. stomach 
b. intestines  
c. liver 
 
76. Which of the following statements is true? 
a. people with CF may need extra fluid and table salt when they exercise 
b. people with CF do not need to exercise 
c. people with CF do not need to exercise if they are doing regular airway clearance 
d. a and c 
 
77. It is generally agreed that the most important part of CF lung care is: 
a. doing your airway clearance treatments everyday 
b. attending all clinic visits 
c. taking your enzymes and vitamins 
d. exercising regularly 
 
78. People with CF:   
a. should eat the same amounts of fat as people without CF 
b. should eat more fat than people without CF 
c.  should eat less fat than people without CF 
d. that amount of fat intake is not important 
 
79. Airway clearance: 
a. should be done every day 
b. can be skipped if you exercised 
c. should be done only when you are sick 
d. is most effective in the morning 
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80. People with CF may need to eat more because:  
a. some energy is lost through malabsorption 
b. they are more active 
c. their metabolism is faster 
d. both a and c 
 
81.  Stomach cramps and gas are signs of: 
a. vitamin deficiencies 
b. hunger 
c. malabsorption 
d.  Stomach cramps and gas are normal in a person with cystic fibrosis. 
 
82. Pulmonary Function Tests (PFTs): 
a. show how your lungs are working at the time of the test 
b. are irreversible 
c. only need to be done once a year 
d. a and b 
 
83. Inhaled antibiotics are generally most effective if done: 
a. before airway clearance 
b. after airway clearance 
c. in the morning 
 
84.  The CF Foundation recommends eating _______ snacks per day. 
a. none 
b. one 
c. two 
d. three 
 
85. Bronchodilators are used to: 
a. remove mucus 
b. open the lung passageways 
c. control bacteria 
d. a and b 
 
86.  If you are using albuterol and TOBI and doing airway clearance, in what order should they be done? 
a.  Albuterol, TOBI, airway clearance 
b. TOBI, airway clearance, Albuterol 
c. Albuterol, airway clearance, TOBI 
d. the order does not matter. 
 
87. Mucus in the lungs is produced: 
a. only in people with CF 
b. only when you get a cold 
c. only when you do airway clearance 
d. none of the above 
 
88. Enzymes are not needed if you eat: 
a. an egg 
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b. an apple  
c. a small piece of chocolate cake 
 
89. For people with CF, coughing: 
a. helps to clear mucus from your lungs 
b. should be done as hard as possible during airway clearance. 
c. is tiring and should be suppressed 
d. should be controlled with cough medicines 
e. a and b 
 
90.  Nebulizers should be disinfected following the manufacturer’s instructions: 
a.  after every use 
b.  once each day that the nebulizer is used 
c. once every 3 days that the nebulizer is used 
d.  once a week 
e. It is not necessary to use Control III as long as the nebulizer is cleaned with soap and water. 
 
91. Which of these foods contain the largest percentage of fat? 
a. potatoes 
b. roast beef 
c. butter 
d. popsicles 
 
92. In addition to airway clearance, some exercises can help loosen mucus. An example is: 
a. weight lifting 
b. running  
c. jumping on a trampoline 
d. both b and c 
e. all of the above 
 
93. Which of the following is a symptom of salt loss? 
a. weakness 
b. fever 
c. muscle cramps or abdominal pain 
d. all of the above 
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